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PrPC is a membrane associated cellular glycoprotein. Its mis-folded form, PrPSc 
causes a set of neurodegenerative diseases called transmissible spongiform 
encephalopathies (TSEs). PrPC is abundantly expressed in the brain tissue and a 
relatively lower expression has been reported in the peripheral tissues. It has 
contradictorily been described to be involved in multiple functions beside the 
consensually accepted function as an anti-oxidant. PrPC has evolutionary conserved 
sequence and it shows that it should have some fundamental functions. The 
functional studies of PrPC in the peripheral tissues could be useful to elucidate its 
fundamental function and to better understand its role in the disease mechanism. 
Among the peripheral tissues, the liver has low PrPC expression, but interestingly its 
expression increases in oxidative stress during the activation of hepatic stellate cells 
(HSCs), which have role in liver diseases. In addition, our first set of results have 
shown a significant up-regulation of PrPC expression in the liver of aging mice (14 
months) as compared to the 3 and 9 months old mice with a differential expression in 
the male and female groups.  
To understand the age and gender dependent altered expression of PrPC and to find 
out that if there was any manifestation of liver diseases, 2D gel electrophoresis based 
proteomics analysis was performed in the liver of PrPC knockout mice (Zürich I). 
Proteins differentially regulated in the liver of PrPC Knockout mice were identified by 
the tandem mass spectrometry (MS/MS). Further, the functional analysis of 
proteomics dataset was performed by using bioinformatics tool called Ingenuity 
pathway analysis (IPA). IPA predicted the manifestations of the liver diseases 
including the fatty liver disease along with the regulation of insulin receptor (INSR) 
and PPARα transcriptional factor. The biochemical measurement of triglycerides and 
the staining of liver tissue by Sudan III confirmed the fatty liver disease in the liver of 
aging PrPC knockout mice. Further, the regulation of apoptotic markers by the 
Western blot indicated the progression of fatty liver disease into non-alcoholic 
steatohepatitis (NASH).  
As majority of the research work in the PrPC knockout mouse models has been 
performed in the brain tissue. Thus, we further performed an additional IPA analysis 
from the same proteomics dataset by setting brain as a reference tissue. This 




analysis included the broader PrPC relevant literature information stored in the 
ingenuity Pathways Knowledge Base (IPKB). It predicted the role of PrPC in cellular 
development, cell signaling, cellular growth and proliferation including the role of 
microtubule associated tau protein (MAPT). Further, by using Western blot analysis 
we observed an age dependent decrease in tau expression and an increase of ptau 
expression in the liver of old age mice. Furthermore, we showed the PrPC dependent 
regulation of ptau by gsk3beta, which is an already known mechanism during prion 
infection. Fatty liver disease has already been described to be associated with the 
imbalance of liver cytoskeleton by the regulation of tau protein expression. Hence, 
our study showed that the absence of PrPC causes the fatty liver disease along with 
associated change in cytoskeleton function in the aging mice liver. In conclusion, 
from this current study, by using PrPC knockout mice, we showed a critical role of 
PrPC in the liver of aging mice by regulating the glucose/lipid metabolism, which 
further seems to be associated with its cytoskeleton function.






2.1 PrPC and prion 
PrPC (c – cellular form) is a cellular glycoprotein and expressed in all the tissues with 
abundant expression in the central nervous system. PrPC protein was discovered 
due to its misfolded disease causing isoform called PrPSc (Sc - scrapie form), which 
has a high beta sheet content compared to its physiological form (PrPC). PrPSc is 
involved in a set of neurodegenerative diseases known as prion (Protein infectious 
particles) diseases or transmissible spongiform encephalopathies (TSE) in humans 
as well as in animals. TSE has been classified based on the infectious, sporadic and 
familial forms. These diseases include Kuru, Creutzfeldt-Jakob disease (CJD) and 
Fatal familial insomnia (FFI) in humans, bovine spongiform encephalopathy (BSE) in 
bovine and scrapie in sheep. All subtypes affect the brain with different pathological 
phenotypes. Prevalence of prion diseases is low, but are incurable and invariably 
fatal (Johnson et al., 2007).  
2.1 Structural features and expression of PrPC 
PrPC is a plasma membrane associated glycoprotein. It is attached to the lipid bilayer 
of the cellular plasma membrane by C-terminal glycosyl phosphatidylinositol anchor 
(GPI) (Stahl et al., 1987). It is synthesized in the endoplasmic reticulum attached 
ribosomes and transported to the cell surface via Golgi apparatus (Harris et al., 
2003). It is attached with two N-linked oligosaccharide chains of high-mannose type 
oligosaccharide at Asn181IleThr and Asn197PheThr of human PrP; asparagine 
residues 180 and 196 of mouse PrP. In addition, there is a single disulphide bond in 
between two cysteines at the C-terminus (Lawson et al., 2005). The cellular PrPC is 
synthesized in three forms: secreted, carboxyl-terminal transmembrane forms 
(PrPctm), and amino-terminal transmembrane forms (PrPntm). The secreted form is the 
main GPI anchor form, which is fully translocated to the ER. With removal of COOH-
terminal signal peptide, GPI anchor is added to immature PrPC in the ER and then 
processed for further transport (Stahl et al., 1987). PrPC is also found in the 
cytoplasm in variable amounts usually after proteasomal inhibition or prnp over 
expression (Alexander et al., 2003). 





In the endoplasmic reticulum, PrPC appears to be associated with the lipid rafts and 
this association has been described to be implicated for the correct folding of PrPC 
(Sarnataro et al., 2004). Certain amounts of PrPC are also transferred to the clathrin-
coated pits, where it is subjected to constitutive endocytosis and recycling 
(Kristiansen et al., 2005). 
PrPC is abundantly expressed in the brain and comparatively low expression in non-
neuronal tissues such as lymphoid cells, lung, heart, kidney, gastrointestinal tract, 
muscle, liver, and mammary glands has been found. (Ford et al., 2002, Isaacs et al., 
2006, Zomosa-Signoret et al., 2007). 
The expression of PrPC starts during embryogenesis (Manson et al.,1992) and its 
transcripts are found at different days of embryogenesis in brain, spinal cord, specific 
non-neuronal cell population such as multi-nucleated cells in the liver parenchyma at 
day 27 (Peralta et al., 2012). The cell specific variant expression of PrPC indicates a 
pleiotropic role of PrPC during development.          
2.2 Phenotypic interpretation of PrPC knockout mouse models. 
Reverse genetics is the first approach to discover the function of a protein by 
knocking out the gene and analyzing phenotypic effects.  
First PrPC knockout mice had been generated in 1992 (Bueler et al., 1992). There 
was great expectation to elucidate the function of PrPC by interpreting the phenotype 
of knockout mice. Unfortunately, PrPC knockout model has not provided any clear 
hint to reveal its fundamental function due to lack of any overt or pathogenic 
phenotype except resistant to prion infection. The resistance to prion infection is 
technically a lack of phenotype. Although, excess amount of literature with diverse 
phenotypes has been accumulated over the years but the results are contradictory. 
Some of these phenotypes are under intensive investigation and many of these are 
subtle (Table 1). As we can see in the table that many phenotypes which have been 
reported are inconsistent among different labs. 
Critical question arise, that which of these phenotypes are related to the primary 
functions of PrPC due to deletion of prnp gene and which could be due to artifacts?  
Unfortunately, PrPC sequence has also not provided any information to predict its 
physiological function. Interestingly, the broad homology conservation of PrPC 





sequence among mammalian and avian species (Fig. 2), expression of the protein in 
almost all tissues during entire lifespan with its high turnover rate gives evidence that 
PrPC have important physiological functions.  
Table 1 – Number of reports describing phenotypes from PrPC knockout mice with parallel 
reports with similar experiments, which are either confirming or opposing the phenotype 
reported in the literature.   
Phenotype in PrP KO Reported Confirmed ? Opposing ? 
Circadian/Sleep regulation 
Abnormal circadian rhythm  Tobler et al., 1996    
Interrupted sleep patterns  Tobler et al., 1996   
Oxidative stress: copper binding, SOD-activity and mitochondria 
Decreased copper content in brain  Brown et al., 1997  Waggoner et. al., 2000 
Decreased SOD activity; increased 
oxidative damage  
Wong et al., 2001 
Brown et al., 2002 
Klamt et al., 2001 Waggoner et. al., 
2000, Hutter et al., 
2003, Lobao-Soares 
et. al., 2005 
Reduction/abnormal mitochondria  Miele et al., 2002  Lobao-Soares et. al., 
2005 
Immune system, phagocytosis and as a microbial receptor 
Increased phagocytosis 47 de Almeida et al., 
2005 
  
Resistance to infection with B. abortus  Watarai et al., 2003  Fontes et. al., 2005
Resistance to infection with HSV-1  Thackray et al., 
2003 
Thackray et al., 2005  
Immune synapse, T cell response  Ballerini et al., 2006   




Impaired long term potentiation  Collinge et al., 1994 Criado et. al., 2005, 
Asante et al., 2004, 
Carleton et. al., 2001, 
Curtis et al., 2003, 
Herms et al., 2001, 
Manson et al., 1995, 
Whittington et al., 1995 
Herms et al., 1995, 
Lledo et al., 1996, 
Maglio et la., 2004, 
Maglio et al., 2006 
Increased susceptibility to seizures  Walz et al., 1999 Rangel et al., 2007  
Mossy fiber disorganization in 
hippocampus  
Colling et al., 1997   
Behavioral phenotypes 
Cognitive defects/memory impairment  Criado et al., 2005 
Coitinho et al., 2003 
Schmitz etz al.., 
2014
 Bueler et al., 1992 
Manson et al., 1994 
Increased locomotor / exploratory 
activity  
Roesler et al., 1999 Criado et al., 2005 
  
 
Increased hyperlocomotion induced by 
MK-801  
Coitinho et al., 2002   
Decreased anxiety  Nico et al., 2005   
Neuroprotection 
Susceptible to Dpl toxicity  Sakaguchi et al, 
1996 
Moore et. al., 1999, Li et 
al., 2000, Nishida et. al., 
1999, Valenti et. al., 
2001 
 





Susceptible to “DF” PrP induced 
toxicity  
Shmerling et al., 
1998 
Flechsig et. al., 2003, 
Radovanovic et. al., 
2005 
 
Enhanced susceptibility to ischemia  McLennan et al., 
2004 
Sakurai-Yamashita et. 
al., 2005, Weise et. al., 
2006, Spudich et. al., 
2005 
 
Enhanced susceptibility to ethanol 
induced apoptosis  
Gains et al., 2006   
Enhanced susceptibility to traumatic 
brain injury  
Hoshino et al., 2003   
Stem/precursor cells 
Impaired self-renewal of hematopoietic 
stem cells  
Zhang et al., 2006   
Decreased proliferation of neural 
precursors  
Steele et al., 2006   
Miscellaneous 




2.3 PrPC function and significance of sequence 
It has been described that PrPC has multiple functions but exact function of PrPC is 
unknown. It is not certain, if loss of function or gain of pathogenic dysfunction of 
PrPSc causes prion diseases. So, exact overlap between gain of pathogenic 
dysfunction of PrPSc and normal physiological function of PrPC is still to be 
determined (Fig. 1). 
 
Fig. 1. The overlapping of region associated with normal physiological function of PrPC and 
pathogenic dysfunction of PrPSc in neurodegeneration.  
2.4 Role of PrPC in aging and oxidative stress 
Although PrPC function is not completely understood, but the role of PrPC as an 
antioxidant and as a neuroprotectant, are among the well characterized and 





consensually accepted functions. Both are linked to the neurodegeneration and aging 
(Vassallo and Herms et al., 2003; Roucou and LeBlanc et al., 2005; Steele et al., 
2008). Recently, the role of PrPC during aging has been described in detail 
(Gasperini et al., 2014). The role of PrPC in aging and oxidative stress is further 
supported by its functional involvement in age related disorders (in addition to CJD) 
such as Alzheimer diseases (Kellett et al., 2009). Thus, it is critical to understand the 
PrPC dependent events during aging such as oxidative stress, changes in PrPC 
expression, localization, biochemical properties, and effect of PrPC knockout on 
phenotypes.  
 
Fig. 2. A) Phylogenetic tree of prnp gene, showing sequence homology conservation among 
mammals and avian species. B) PrPC sequence with conserved regions: hydrophobic 
region, residues with disulphide bonds and glycosylation sites.  
Furthermore, PrPC reduces the formation of reactive oxygen species (ROS) due its 
ability to catalyze the reduction of Cu2+ into Cu+ (Gasperini et al., 2014). Further, it 
has been reported that PrPC knockout mice possess high sensitivity to the neurons 
due to oxidative stress (Brown et al., 1997, Rachidi et al., 2003). Another report 
described the impairments in copper incorporation in PrPC knockout mice due to 
alterations of superoxide dismutase (SOD I) enzyme activity (Brown and Besinger et 
al., 1998, Kralovicova et al., 2009). One experimental approach on neuronal cell lines 
devoid of PrPC has shown the trigger of apoptosis after serum removal. In addition, 
neuronal cell lines were more sensitive to oxidative stress due to mitochondrial 





dysfunction compared wild type, indicating a neuro-protective function of PrPC (Kim 
et al., 2004). PrPC knockout mouse has also been reported to have higher levels of 
lipid and protein oxidation, which are the marker of cellular damage due to oxidative 
stress (Wong et al., 2001). At molecular level, beta cleavage of PrPC protein has 
been linked with role of PrPC against oxidative stress (Watt et al., 2005). 
2.5 Change in behavioral phenotypes during aging 
The role of PrPC in learning has been associated due to two major observations: 1) 
PrPC expresses predominantly in neurons with highest expression in hippocampus 
(De Armond et al., 1987; Benvegnu et al., 2010), 2) The expression of PrPC 
increases in the brain during aging (Williams et al., 2004). One comparative study in 
PrPC knockout, wild type and PrPC over expressing mice have shown that PrPC has 
a role in regulating age dependent alterations in anxiety like responses, in locomotion 
and defects in short-term social recognition memory.  
Further, our group showed the drop in anxiety and decline in associative learning in 
the aging PrPC knockout mice. We have reported that the PrPC dependent 
alterations in cytoskeleton protein expressions could be responsible for change in the 
learning process (Schmitz et al., 2014).  
In conclusion, PrPC dependent change in cognitive learning and behavioral activities 
in aging mice could be linked to the increase of oxidative stress and decrease of 
neuroprotective function of PrPC.  
2.6 Change in biochemical properties of PrPC in aging 
2.6.1 Glycosylation patterns 
PrPC is glycosylated at two specific sites, which represents three different bands in 
Western blot: di-glycosylated (35 KDa), mono-glycosylated (32 KDa) and 
unglycosylated (28 KDa) (Khalili-Shirazi et al., 2005; Pan et al., 2002). It has been 
reported that during aging, N-terminally truncated and under glycosylated (mono- and 
un-glycosylated) full length PrPC species increase with the age (Goh et al., 2007).  
Further, the accumulation of under-glycosylated and N-terminally truncated PrPC in 
both aging and prion infection suggests the functional relevance of PrPC 
glycosylation in aging processes.  





2.6.2  Localization  
PrPC is a GPI-anchored protein and it has been associated with lipid rafts. PrPC 
protein is transported from the detergent soluble membrane fractions to lipid rafts 
compartments in aged mouse hippocampus (Agostini et al., 2013). During normal 
aging brain or in neurodegenerative diseases like AD, there has been a change in 
cholesterol/sphingolipid ratio (Martin et al., 2010). Hence, the localization of PrPC 
might potentially be affected due to age dependent changes in the membrane 
composition and hence it may also modulate the function of PrPC.  
2.7 Role of PrPC in age related neurodegenerative diseases 
PrPC expression increases in brain with age, which could be linked with its functional 
role as an anti-oxidant against increased oxidative stress in the old age (Williams et 
al., 2004). 
In neurodegenerative diseases such as CJD and AD, it has been reported that PrPC 
expression decreases in the brain and CSF, which could be associated with an 
increase in oxidative stress due to low PrPC expression or the other way, 
neurodegenerative diseases could be one of the cause which leads to low PrPC 
expression. At molecular level, it is known that PrPC regulates the processing of 
amyloid precursor protein and production of Aβ, a hallmark of AD (Parkin et al., 
2007). In addition, higher production of Aβ has been reported in the brains of PrPC 
knockout mice (Parkin et al., 2007). So, decrease in PrPC expression in 
neurodegenerative disorders could be part of the mechanism which has been linked 
with the higher Aβ synthesis in disease.  
So, based on expressional profiles of PrPC during aging and its involvement in age 
associated neurodegenerative diseases, it seems that PrPC has an important role in 
aging.  
2.8 Role of PrPC in peripheral tissues 
Most of the PrPC functional research has been performed in the brain or neuronal 
cell lines. To elucidate the fundamental function of PrPC, it is important to consider its 
functional relevance in the peripheral tissues as well because it is ubiquitously 
expressed in almost all the tissues. Not much attention has been given to explore the 





role of PrPC in peripheral organs. There are some reports based on PrPC functional 
studies in peripheral tissues with a brief following outlook:  
2.8.1 Spleen 
PrPC is highly expressed in follicular dendritic cells (FDC) of spleen. But no effect on 
the development or maturation of FDC cells has been reported in the PrPC knockout 
mice. Further, it has been reported that the knockout of PrPC has no effect on the 
immune function neither to bind immune complexes on the surface nor to produce 
antigen-specific antibodies. This also implies that PrPC function is beyond its 
expression levels which might be related to a specific cell type or specific 
physiological conditions. (McCulloch et al., 2013).  
2.8.2 Liver  
Among peripheral tissues, the expression of PrPC in liver is comparatively low but 
interestingly, it has been reported that PrPC expression increases during oxidative 
stress conditions such as CCl4 induced liver fibrosis due to the activation of hepatic 
stellate cells (Ikeda et al., 1998).   
2.8.3 Muscle  
One study has been done on skeletal and cardiac muscle tissue in the PrPC 
knockout mice. It showed that PrPC might has an important role in mitochondrial 
dependent locomotory activity especially during exercises (Nico et al., 2005). This 
shows that PrPC has a role in muscle physiology and possible involvement in the 
neuromuscular pathologies.  
2.8.4 Intestine   
PrPC knockout mice showed greater paracellular permeability in the intestine as cell-
cell junctions and monolayer shape were altered in the PrP knock down cells. 
Further, E-cadherin,  plakoglobin, claudin-4, desmoplakin, occludin, zonula occludens 
1, and tricellulin were decreased at cell contacts while re-introduction of PrPC 
restored cell shape and junctions, which shows that PrPC may regulate intestinal 
barrier and epithelial cell-cell junctions functions (Petit et al., 2012). Another study in 
mucous epithelial cells of stomach and intestine has shown the localization of PrPC 
in the secretary globules of digestive tract which emphasize the role of PrPC in the 
secretary function of digestive tract (Fournier et al., 1998).  





2.9 Liver: A model tissue to study PrPC function 
As emphasized above, not much research has been done in peripheral tissues.  The 
current project is to define the role of PrPC in peripheral tissues with liver as a model 
due to following reasons: Liver is the most important metabolic organ with highest 
ability of proliferation and regeneration. It is physiologically and functionally linked 
with almost all the tissues of the body. In addition, there are a large number of sex-
dependent regulated proteins influenced by hormones in the liver (Waxman et al., 
2009), so it could also be a useful organ to explain, if any gender specific role of 
PrPC. The relationship between the brain and liver in relevance to physiological 
function and neurological disorders has been known for years (Lewis et al., 2003). 
Interestingly, the presence of prion infectivity in the liver of sheep, experimentally 
infected with BSE and the presence of prion deposits in the liver of inherited human 
prion disease has been reported (Everest  et al., 2011, Mead et al., 2013). In 
addition, liver has also been shown to be a significant source of Aβ synthesis and 
linked with brain pathology in the mouse model of Alzheimer’s disease (Sutcliffe et 
al., 2011).      
In literature, it has been described that the expression of PrPC in liver is low, which 
might be due to the fact that most of the previously published reports in the liver had 
been done in the embryonic stage, young or adult mice (Ford et al., 2002, Horiuchi et 
al., 1995; Moudjou et al., 2001; Peralta et al., 2012). Interestingly, the proliferation of 
hepatic stellate cells (HSCs) during CCl4 induced fibrosis results in the up-regulation 
of PrPC expression both at mRNA as well as protein level due to increase in 
oxidative stress (Ikeda et al., 1998). This indicates that PrPC has some important 
functional link with hepatic stellate cell activation. The precise function of hepatic 
stellate cells is not known. Notably, HSCs have been described to be activated during 
various liver diseases which are associated with liver injury, such as fatty liver 
disease (Washington et al., 2000). The role of PrPC during oxidative stress in the 
aging mice via regulation of SOD1 has already been known (Vassallo and Herms, 
2003; Roucou and LeBlanc, 2005; Steele et al., 2008, Gasperini et al., 2014) and 
activation of HSCs has also been linked with increased oxidative stress during liver 
injuries. Interestingly, the liver is the tissue with the highest SOD1 enzyme 
expression (De Haan JB et al., 1994). It implies that PrPC might have an important 
function, linked with pathophysiological conditions in the liver due to increased 





oxidative stress. Recently, our group has reported the higher latency in open field test 
in the aging PrPC knockout mice as compared to the wild type possibly due to 
alterations in the cytoskeleton function (Schmitz et al., 2014).  
Interestingly, similar changes in the anxiogenic effects has been reported in the rat 
model due to liver damage induced by lipopolysaccharide (LPS) in which rats spent 
more time in the closed arms of open field test (Anjali et al., 2006). 
In addition, another study has reported the reduced anxiety in the rat model due to 
cafeteria (CFA) induced increased triglycerides deposition in the liver and increased 
insulin resistance (Lalanza et al., 2014). So, alterations in behavioral activities in the 
PrPC knockout mice model at least could partially be linked with the change in liver 
function because any alterations of liver function may potentially affect the central 
nervous system functions including behavioral manifestations (Nguyen et al., 2012).   
Based on the above evidences, we hypothesized that PrPC expression should be 
increased during aging process in the liver due to its role as an anti-oxidant and it 
might also be linked with the liver disease pathology due to its reported role in HSCs 
activation and altered behavioral activities.    
2.10 PrPC knockout mouse models: Importance of Zurich I 
To study the mammalian gene function, gene-targeting and transgenic mouse 
models are often generated. This strategy has also facilitated the in vivo study of 
PrPC function. The gene knockdown technology expected to show changes in the 
phenotypes of mouse such as appearance, behavior and biochemical characteristics, 
so observing any differences from normal behavior or physiology, researchers can 
infer its probable function. Over the three decades of intensive research, a number of 
different mice and other animal models have been employed to understand the 
disease mechanisms and function of PrPC itself.  Among the notable models, mice 
with PrPC over-expression and PrPC knockout mouse model are of central 
importance. The interpretation of the PrPC function gave a contradictive outcome 
when PrPC knockout mice showed no obvious phenotype. PrPC is encoded by a 
single-copy gene (Basler et al., 1986) that comprises three exons, with the entire 
reading frame contained in the third exon (Fig. 3).  A number of mice lines devoid of 
PrPC have been generated using two strategies: 1) Conservative strategy and 2) 
Radical strategy.   





Conservative strategy: It involves the truncation modifications only to the open 
reading frame (ORF). PrPC knockout mice with a conservative strategy develop 
normally without any pathological phenotype and are resistant to prion infection.  
Radical strategy: In this strategy, in addition to the reading frame, it also involves 
the deletion of flanking region, particularly, splice acceptor site of the third exon. Mice 
with this strategy also develop normally, but exhibits severe ataxia and Purkinje cell 
loss in later stage life (Sakaguchi et al., 1996, Moore et al., 1999, Silverman et al., 
2000, Rossi et al., 2001). However, later on it was found that phenotype associated 
with the radical strategy was due to ectopic expression of Dopple product, caused by 
transcription of prnd gene which is 16bp downstream of prnp gene. The ectopic 
expression of Dopple was likely to be caused by the deletion of sequences flanking 
the prnp ORF. Deletion of splice acceptor site of the third prnp exon caused the 
formation of chimeric transcripts that placed prnd transcription under control of prnp 
promoter. So all three PrPC knockout mice generated by radical strategy: Nagasaki, 
Zürich II and Rcm0 are not reliable because of the fact that generated phenotype 
was not caused by the absence of prnp gene but due to the expression of Dopple 
gene product.   
Mice generated with conservative strategy: Zurich I and Edinburg are the most 
reliable models compared to models generated by radical strategy. Zurich I is the well 
characterized and easily available model while Edinburg has breeding problems due 
to pure background (Payne et al., 1998). So, based on its advantages, we have used 
Zurich I mice in the current study.   






Fig. 3. Strategies of PrPC knockout mouse and their phenotypes: (a) various ways of 
gene targeting by homologous recombination. Black boxes shows ORFs of PrP; white boxes 
– non coding regions of the gene; grey boxes – insert sequences; dotted line – removed 
regions; neo stands for neomycin phosphotransferase; HPRT for hypoxanthine 
phosphoribosyltransferase; loxP is represented with black arrow-head is a 34 bp site of 
recombination from phage P1. (b) Different coding and noncoding sequences of Prnd, Prnd 
and intergenic coding sequences of unknown function. (c) Doppel expression under Prnp 
promoter by exon skipping. (d) Comparison of different regions of Doppel (Dlp) to the full 
sequence of PrP and PrP sequence that lacks 32-134 residues (Figure was obtained from 
the reference – Weissmann et al., 2003).  
2.11 Proteome/genome wide functional analysis of PrPC  
Most of the proteomics or genomics based PrPC functional studies have been done 
in brain or cell lines. One proteomics based approach implying 2D gel electrophoresis 
technique to compare brain proteome of the Zurich I PrPC knockout mice has shown 
no significant differences between PrPC knock out and wild type mice. This study has 
shown that proteome of PrPC knockout mice compared with wild type mice is highly 
conserved unlike transcriptome studies which have shown a significant amount of 
gene regulation between PrPC knockout mice as compared to wild type mice. 
Contrary to study in the brain, an another study based on proteomics using PrPC 





deficient  human embryonic kidney (HEK) cell line and transient PrPC expressional 
levels in PrPC deficient cells was performed. The results from this study showed the 
regulation of proteins involved in energy metabolism, cellular homeostasis, oxidative 
stress and apoptosis. 
Interestingly, this proteomics based approach has first time shown PrPC dependent 
regulation of several proteins involved in the pathogenesis of Alzheimer disease 
(Ramljak et al., 2007). 
Further, one genomics study involving microarray in PrPC knockout mouse model 
has shown a number of regulated genes which are related to neurodegenerative 
pathways such as Alzheimer disease. This report has described 18 up-regulated 
genes and 12 down regulated genes among which Ch25h, S100a9, Kcnip3, Grin2b, 
Cdk5r1, Cdk5, Psen1, and Sod2 were up regulated, whereas genes such as Gsk3 
were down regulated in the developmental stages of Prnp0/0 mice (Benvegnù et al., 
2011). Further bioinformatics interpretation of the genomics data has shown a link of 
PrPC function in amyloid processing pathways, specifically the genes involved in tau 
phosphorylation (Benvegnù et al., 2011). Tau protein is a microtubule associated 
protein which stabilizes the microtubule and its hyper phosphorylation causes 
misfolding of tau protein molecules. It forms paired helical filaments (PHF), which are 
very well known to be the structural constituents of neuro-fibrillary tangles in 
neurodegenerative Alzheimer disease (AD) (Fig. 4). Tau protein is highly 
phosphorylated in normal developing brain (Mawal-Dewan et al., 1994), probably to 
maintain microtubule polymerization-depolymerization dynamics during brain 
development. It has been reported that there is age dependent decrease in total tau 
protein and phosphorylated tau both in PrPC knockout and wild type mice (Benvegnù 
et al., 2011). The levels of phosphorylation are known to be higher in the brain of 
newborn PrPC knockout mice as compared to the wild type mice. But there has been 
no PrPC specific regulation in the adult mice. Studies have shown that PrPC 
regulates the phosphorylation levels of tau during post natal developing brain (Caiati 
et al., 2013). This involvement of PrPC in tau pathways indicated the role of PrPC 
during development and shed a light on a correlation between AD and prion biology.   
Specifically, genomic and proteomic studies investigating PrPC knockout mice and 
cell lines have given new insights to explore PrPC function.  





2.12 Hypothesis and objectives 
Finally based on the above evidences, we hypothesized: 
1. Age dependent altered regulatory response of PrPC expression in liver.  
2. Potential gender specific outlook to the PrPC function due to high sex 
dependent hormonal influence of the liver tissue.  
3. PrPC knockout mice liver might have some pathological manifestations due to 
its reported role, specifically in the hepatic stellate cells (HSCs) activation.  
4. Proteomics based approach could generate correlative functional links with 
previous proteomics/genomics based studies in the brain of PrPC knockout 
mice and may help to elucidate its fundamental role.  
So, first we used livers from 3, 9 and 14 months old wild type mice (C57BL/6) to see 
the age and gender dependent expressional profile of PrPC. Second, based on 
previous reports from proteomics and genomics studies, we performed 2D gel 
electrophoresis based protein profiling in the liver of Zürich I PrPC knockout mice 
from the same three age groups.  
 
 




3 Materials and Methods 
3.1 Animals 
We used Zürich I PrPC knockout and wild type mice with C57BL/6 background. 
Three different age groups (3 months, 9 months and 14 months old of male and 
female) were used in this study. All experiments with the involved animals were 
performed in accordance with the relevant laws and institutional guidelines of Central 
Animal Facility, UMG, Göttingen. 
3.2 2 Dimensional (D) gel electrophoresis 
3.2.1 Sample preparation.  
After mice being sacrificed, liver tissue were dissected and were snap frozen into 
liquid nitrogen and stored at -80°C until further use. The tissues were lysed in tissue 
lyses buffer (7M urea, 2M thio-urea, 4 % CHAPS, 20 µl/ml ampholytes, 10mg/ml 
DTT, protease and phosphatase inhibitors) for 5 minutes at 50 hertz frequency and 
kept at 4°C for overnight. Lysed tissue samples were centrifuged at 14000 rpm for 20 
minutes at 4°C and supernatant was obtained for further protocols.  
3.2.2 2D gel electrophoresis, staining and image Analysis 
Protein concentrations were measured by the Bradford protein estimation method 
(Bio-Rad standard protocol) and lysates volume containing 120 µg of protein were 
diluted into 325 µL rehydration buffer (7M urea, 2M thio-urea, 4% CHAPS, 0.2% 3-10 
bio- Lytes and 65mM DTT) and loaded on a ReadyStrip (IPG nonlinear pH 3-10, 17 
cm strip – Bio-Rad). After 12 h of active rehydration at 50 volt (V), isoelectric focusing 
was started at 500 V for 1 h, followed by ramping at 1000 V for 1 h and 5000 V for 2 
h. The final focusing was conducted at 8000 V, reaching the total of 60,000 V hours 
(PROTEAN IEF CELL, Bio-Rad). Then, the strips were equilibrated 2 times for 20 
minutes in buffer containing 6M urea, 2% SDS, 30% glycerin, and 0.375M Trisph, pH 
8.8, supplemented with 2% DTT in the first and with 2.5% Iodoacetamide (IAA) in the 
second equilibration step. SDS-PAGE was performed overnight at 4°C with 
homogeneous 12% polyacrylamide gel using a PROTEAN II XL Vertical 
Electrophoresis Cell (Bio-Rad). 
2D gels were stained with silver staining – Gels were placed in fixative (50% 
methanol, 12% acetic acid), washed with 50 and 30% ethanol, sensitization with 




1.26mM sodium thio-sulphate, staining of gels with the silver nitrate (1g/liter silver 
nitrate, 700 µl formaldehyde/liter), developing (60g/liter Sodium carbonate, 500 µl 
Formaldehyde/liter, 40 µl of 10% sodium thio-sulphate), and finally stopping of the 
reaction with fixative.  The images were scanned at 300 dpi with canon LiDe 110 
scanner. Protein spot abundances from 48 liver proteome gel images (3, 9, 14 
months, wild type and PrPC knockout from both gender) were analyzed using the 
Delta2D software (v. 3.6) (DECODON). The differences in spot abundance detected 
by Delta2D densitometry analysis were statistically evaluated using unpaired 
Student’s t-test. Means and standard deviations were calculated from four sets of 
experiments. A protein spot was considered as differentially regulated when its 
densitometric analyses showed at least 1.5-fold change in abundance and when the 
p-value was <0.05 in unpaired Student’s t-test. 
3.3 In gel digestion and mass spectrometry identification 
2D gel spot plugs containing proteins (differentially regulated spots) were manually 
excised from the silver stained gels and subjected to in-gel digestion. The detailed 
protocol of this procedure has been described by Ramljak (Ramljak et al., 2007). In-
gel digested peptides were chromatographically separated (C18 pepMap100 Nano 
Series analytical column, LC Packings) and analyzed by an ESI-Q-TOF Ultima 
Global mass spectrometer (Micromass). Data acquisition were performed using the 
MassLynx (v. 4.0) software and further processed on Protein- Lynx-Global-Server (v. 
2.1) (Micromass). The acquired data was searched against MSDB and SwissProt 
2010_08 databases through the Mascot search engine using a peptide mass and 
MS/MS fragment mass tolerance of 0.5 Da. The searching criteria were set with one 
missed cleavage by trypsin allowed and protein modifications included methionine 
oxidation and carbamidomethyl cysteine when appropriate.  
3.4 Screening of mass spectrometry data 
Raw files in the scaffold software format were further screened to remove false 
positive results based on the following criteria:  
a) Molecular mass – As each protein has its unique molecular mass, therefore 
identified protein was confirmed, if it was from the excised spot by comparing the 
theoretical molecular mass of the protein with the experimental molecular mass on 
the gel map with help of a maker.  




b) Isoelectric pH (pI). – As each protein has its unique isoelectric pH, so the 
theoretical pI was compared with the experimental pI on the gel maps.  
c) Score/peptide count – Peptide count is the number which represents the number 
of times a peptide has been detected by the mass spectrometer. We set up a criteria 
minimum of 5 counts to be considered for the further functional analysis.  
d) Sequence coverage – It is the percentage of the sequence covered by the peptide 
identified, out of the full sequence of the protein. We set up minimum sequence 
coverage of 15% to include the identified protein in our study.  
3.5 Western blotting.  
3.5.1 Preparation of mice liver samples  
Mice were sacrificed and liver tissue was frozen in liquid nitrogen. Liver tissue was 
lysed with Urea/thio-urea lysis buffer (7M urea, 2M thio-urea, 4 % CHAPS, 20 µl/ml 
ampholytes, 10mg/ml DTT, protease and phosphatase inhibitors) and kept at 4°C 
overnight before centrifugation at 14000 rpm for 20 minutes.  
3.5.2  Liver homogenate 
Liver samples were homogenized and lysed with the similar protocol as described 
earlier for 2D gel electrophoresis. Liver tissue lysates containing 75 µg of protein 
samples were separated on 12% SDS-PAGE gels and transferred to PVDF 
membranes. The membranes were blocked with 5% skimmed milk in phosphate 
buffer saline with 0.2% Triton X-100 (PBST) for 1 h at room temperature. 
Subsequently, the membranes were incubated overnight at 4°C with the following 
primary antibodies: mouse anti-PrPC SAF32 (SPI-BIO), rabbit anti-Tau (1:1000, 
Abcam), mouse anti-Ptau-199 (1:1000, Abcam), mouse anti-Beta-actin (1:2000, 
Abcam), mouse anti-Gsk3beta (1:10000, Santa Cruz), mouse anti-Pgsk3beta 
(1:1000, Milipore), rabbit anti-CDK5 (1:1000, Santa Cruz), rabbit anti-P25 (1:1000, 
Cell Signalling) mouse anti-Bax (1:1000, Cell Signalling), mouse anti-Bcl2 (1:1000, 
Cell Signalling). Thereafter, membranes were washed with PBST and incubated for 1 
h at room temperature with the corresponding horseradish peroxide-conjugated 
secondary antibodies: (goat anti-mouse; 1:10,000, Abcam, anti-rabbit; 1:7500, 
Jackson Immunoresearch). The immunoreactivity was detected after immersing the 
membranes in enhanced chemiluminescence (ECL) solution (Index) and the 
membranes were scanned with ChemiDoc fluorescent device (Bio-Rad). Films were 




scanned, densitometry and statistical analysis were performed with the Image Lab 
Software. The protein regulation was considered significant when the P-value was 
lower than 0.05 in student’s t-test. 
3.6 Immunofluorescence 
Frozen liver tissues were embedded in cryomatrix and 5 µm thick sections were 
sliced using cryostat (Leica cryostat 3050). These sections were mounted on 
histological glass slides, fixed in acetone (1 minute), washed with methanol (10 
minutes), and air dried. Slides were kept at -20°C until further use. 
Immunofluorescence staining was performed using the following protocol: 
 The tissue glass slides containing liver tissue sections were thawed at room 
temperature for 10-20 minutes 
 Slides were rehydrated in wash buffer (PBS) for 10 minutes 
 Tissue sections were surrounded by drawing a hydrophobic barrier circle using 
fat PAP pen marker 
 To expose the antigenic site in the tissue sections, slides were incubated in 
PBS supplemented with 0.2 % Triton X-100 
 Primary antibodies were applied in appropriate dilutions and slides were 
incubated overnight at 40C 
 Washing was done with PBS (3x, 5 minutes) followed by incubation with 
secondary antibody for 1h at room temperature. 
 Washing with PBS (3x, 5 minutes) was done. 
 Slides were air dried and mounted with the cover slips using antifade mounting 
medium  
 Slides were visualized using a fluorescence microscope. 
3.7 Measurement of fat in liver tissue 
The analysis of the fat content was performed histochemically by Sudan III staining 
on liver tissue sections and a quantitative measurement of the total triglycerides 
content was performed in diagnostic facility at the department of clinical chemistry, 
UMG, Göttingen. 




3.7.1 Sudan III staining 
The tissue slices of 5 µm thickness from the liver samples were sliced with cryostat 
and fixed with 4% paraformaldehyde.  
 The tissue glass slides containing liver tissue sections were thawed at room 
temperature for 10-20 minutes 
 The slides were rehydrated in wash buffer (PBS) for 10 minutes 
 Tissue sections were surrounded drawing a hydrophobic barrier circle using 
fat PAP pen marker 
 The slides were washed with 50% ethanol   
 After being washed with 50% ethanol, slides were incubation with ready to use 
Sudan III dye for 5 minutes.  
 The slides were washed again with 50% ethanol for 10 seconds, followed by 
washing with distilled water for 10 seconds.  
 After being washed, slides were incubated with ready to use hematoxylin for 5 
minutes followed by washing with tap water for 10 minutes.  
 Slides were air dried and mounted with cover slip using anti fade mounting 
medium  
 Slides were visualized using a bright field microscope. 
3.7.2 Triglyceride content  
Liver tissue was homogenized in PBS. The homogenates were centrifuged at 14000 
rpm for half an hour and supernatant was obtained. The supernatant from the liver 
homogenates were then analyzed for the triglyceride measurement (mg/dl) by the 
diagnostic facility at the department of clinical chemistry, UMG, Göttingen.  
3.8 Capillary Electrophoresis 
Free-zone Capillary electrophoresis (CE) was performed on a Beckman P/ACE MDQ 
Capillary Electrophoresis System controlled by 32 Karat 7.0 Software (Beckman 
Instruments). LIF detection was performed by an air-cooled argon laser (Beckman 
Instruments) with excitation at 488 nm and emission at 520 nm. The untreated fused-
silica capillaries (Beckman Coulter) with an inner diameter of 50 mm and a total 
length of 30 cm (20 cm to the detector) were preconditioned with, 0.1 M NaOH, H2O 
and 5mg/ml CM-β-CD running buffer. The peptide was labeled during synthesis 
through a gamma butyric bridge. Rabbit antibodies were produced to peptide and 




affinity purified by passing over an affinity column prepared with the corresponding 
peptide. Peptides and antibodies were obtained from Ames Laboratory, USDOE, 
Iowa State University, Ames, IA, USA. The dilutions of antibodies and peptides were 
made to determine the concentration that gave the ratio equal to 1.00 and were 
prepared in the 25mM TAPS (pH 8.8) buffer with 0.1 % BSA. 
3.8.1 Sample preparation and capillary immunoassay 
After mice being sacrificed, liver tissues were excised into liquid nitrogen and 
immediately stored at -80°C. Tissues were lysed in lyses buffer containing 3 ml 1 M 
Tris-Cl, pH 7.5, 3 ml 5M NaCl, 10 ml 20% CHAPS 84 ml ddH2O and protease 
inhibitors for 5 minutes at 50 hertz frequency and kept at 4°C for overnight. Lysed 
tissue samples were centrifuged at 14000 rpm for 30 minutes at 4°C and supernatant 
was obtained. Analysis was performed within half an hour after samples were 
prepared to load. Running method was described in the literature (Yang et al., 2005). 
Peak areas for the free FITC-peptide and immunocomplex (antibody+tissue lysate) in 
electrophoretograms were measured and their ratio was calculated. The ratio was 
multiplied by peak area of the control immunocomplex (antibody+buffer) to obtain the 
normalized values for different set of experiments.  
3.8.2 Calculations (Expression of PrPC):  
We observed a variation in the peak area with the same set of antibody dilutions from 
one set of experiment compared to another. Therefore, to compare different 
experiments performed on different types of tissues, we normalized the different set 
of immunoassays by calculating a normalized Ratio (R).  It was determined by 
calculating the area under the peak of the free peptide vs area under the peak of the 
antibody control (antibody + buffer + free peptide). Ratio obtained was multiplied by 
area under the peak of PrPC (antibody+tissue lysate+free peptide). This gave the 
relative amount of PrPC expression (Table 1).  
Three types of peaks were obtained as shown in figure 6: (1) Free FITC-peptide 
peak, (3) Antibody (Ab) control peak and (2) PrPC peak 
Normalized ratio (R): Area of free peptide peak (1) /Area of ab control peak (3) 
Relative expression of PrPC: Ratio × Area of PrPC peak (2) 
 




Table. 2. Calculations to measure the expressional levels of PrPC in brain and 
liver 
Sample Area under the 
peak (PrPC) 
/100000 
Area under the 
peak (Free 
Peptide)/100000 








Brain 2.04 3.16 0.19 16.73 34.09 
Liver 1.05 2.53 0.78 3.25 3.42 
 
 
Fig. 5. Relative expression of PrPC and binding of peptide at different dilutions of 
antibody: (A) PrPC expression in the liver and brain by peak area (Table 2). (B), Different 
dilutions of the antibody incubated against 1/100 K dilution (0.5mg/ml) of the peptide.  
3.9 Quantitative Real-Time PCR (qPCR) 
Sample preparation and total RNA extraction from the liver tissue was done as per 
instructions from a commercial kit (mirVana isolation kit Ambio, Austin, TX). The 
retrotranscriptase reaction of the RNA samples was carried out with the High 
Capacity cDNA Archive kit (Applied Biosystems, US) following the protocol provided 
by the manufacturer and using the Gene Amp® 9700 PCR System thermocycler 
(Applied Biosystems, USA). A parallel reaction for an RNA sample was run in the 
absence of reverse transcriptase to assess the degree of contaminating genomic 
DNA. Roche LightCycler 480 detector instrument was used for PCR amplification and 
detection. Parallel amplification reactions for each sample were performed using the 
20 × TaqMan Gene Expression Assays (Applied Biosystems) and 2 × TaqMan 
Universal PCR Master Mix (Applied Biosystems). Different steps were as follows: 
denaturation-activation cycle (50°C for 2 minutes, 95°C for 10 minutes) followed by 




40 cycles of denaturation-annealing-extension (95°C, 15 seconds; 60°C, 1 minute; 
98°C). mRNA levels were calculated using the LightCycler 480 software. Data 
analysis was done by ∆∆Ct method to get PrPC gene expression values as fold 
changes between two genders, which were normalized by the relative expression of 
a housekeeping gene (HPRT). The probes used in this study:   
1. PrPC–TCGGTGGCAGGACTCCTGAGTATAT  
(Life technology- Mm01545186_m1) 
2. HPRT- GTTAAGGTTGCAAGCTTGCTGGTGA  
(Life technology- Mm00446968_m1) 
 
 
Fig. 6. Electrophoretograms of PrPC expression by capillary electrophoresis (CE) in 
brain (A) and liver (B) respectively: Peak 1 represents (Free FITC-peptide), peak 2 
represents (Antibody + FITC-peptide + tissue lysate) and peak 3 represents antibody control 
(antibody + FITC peptide). Relative Fluorescence Units (RFU). 




3.10 IPA Analysis 
Ingenuity Pathway Analysis (IPA) is a web-delivered application (www.ingenuity.com) 
that transforms a list of proteins/genes (with or without accompanying expression 
information) into a group of relevant biological networks based on the literature 
records maintained in the Ingenuity Pathways Knowledge Base (IPKB). This 
knowledge base has been integrated into a large network, called the Global 
Molecular Network, composed of thousands of genes and gene products such as 
proteins or compounds with their interacting partners.  
Principle: Each protein identifier such as accession numbers were mapped to its 
corresponding protein object in the Ingenuity Pathways Knowledge Base (IPKB). The 
biological networks were generated based upon the identities of the focus proteins 
and interactions with genes/proteins that were reported in the literature. Each 
biological network has a significance score, which was created using a P-value 
calculation. The P-value indicates the likelihood that assembly of a set of focus 
proteins in a network could be explained by the random chance ﴾ (Score) p-score = - 
log10 (P-value)  ﴿ . For example, a score of 2 indicates that there is 1 in 100 chance 
that focus proteins are together in a network due to random chance. Therefore, 
networks with scores of 2 or higher have at least a 99% confidence of not being 
generated by random chance alone.  Calculation of canonical pathways/biological 
functions were assigned by using research extracted from scientific literature and 
stored in the IPKB.  
Settings: IPA provided a wide range of settings such as to select species/strain 
taken (i.e., mouse, human etc.), experimental type (i.e., proteomics, microarray etc.), 
tissue used (i.e., brain, liver etc.). In our study, we performed two type of analysis: 
first was performed using liver as a reference tissue and second was an additional 
analysis with brain as a reference tissue because most of work with prion transgenic 
mouse models or prion disease human subjects is done in brain and only two reports 
have been published in liver so far. Therefore, the second analysis was aimed to get 
the additional information regarding the fundamental function of PrPC.   
 
 





PrPC expression in the liver is very low. Therefore, we used high sensitive capillary 
electrophoresis (CE) technique along with Western blot to obtain the improved 
resolution of PrPC expression. Gender dependent expression of PrPC was observed 
in the liver. In this study, we observed that PrPC expression increased with age and 
was found maximum in the aging wild type mice liver (14 months old). The proteome 
profiling of all the age groups from the PrPC knockout mice liver showed 64 
differentially regulated proteins. Further IPA software analysis and confirmation by 
Sudan III (fat globules) staining showed the manifestations of the fatty liver disease. 
Additional IPA analysis showed the regulation of microtubule associated tau (MAPT) 
protein which was further confirmed by Western blot and immunofluorescence.     
4.1 Age and gender dependent PrPC expression in mice liver 
4.1.1 mRNA expression of PrPC 
The mRNA expression of PrPC from all three age groups was quantified by qPCR. 
The female mice have higher PrPC expression than male mice in the liver of 9 and 
14 months. The expression of PrPC was higher in the 14 months old wild type mice 
liver as compared to the 3 and 9 months of age (Fig. 9). Further, we analyzed the 
PrPC expression at the protein levels. It was critical to measure the expression of 
PrPC first at the gene level, because its detection at the protein level could be due to 
its amounts in the liver from 
 
Fig. 9. mRNA expression of PrPC in 3, 9 and 14 months old wild type mice liver: PrPC 
expression was significantly higher in the female as compared to male wild type mice liver in 




the 9 and 14 months old  age and a similar gender dependent trend of PrPC expression in 
the 3 months old age mice was also observed (F-Female, M-Male). 
systemic circulation as liver is physiologically linked to other tissues through hepatic 
portal system. 
4.1.2 The expression of PrPC at protein level  
The expressional regulation of PrPC at protein level was analyzed by high sensitive 
technique capillary immunoelectrophoresis (CIE) and Western blot.  
4.1.3 Analysis of PrPC expression by Capillary immunoelectrophoresis (CIE) 
The main advantage of capillary immunoelectrophoresis (CIE) is its high sensitivity, 
with a detectable limit of 1pg (Yang et al., 2005), which is difficult to be achieved with 
the standard techniques like Western blot or ELISA. By implying CIE, we observed a 
better resolution of PrPC differential expression in the 9 months old age mice liver 
(Fig. 10B). However, PrPC was barely detectable by standard techniques such as 
Western blot or ELISA. However, by CIE showed the higher expression of PrPC in 
the liver of 9 months female mice as compared to the male wild type mice. Identical 
regulation was observed in the 14 months old mice (Fig. 10C and 10D).  
 
Fig. 8. PrPC expression in wild type compared to the PrPC knockout liver: Expression 
of PrPC in wild type (peak 1) and PrPC knockout mice (peak 2). PrPC expression in PrPC 
knockout liver was equivalent to antibody control (peak 3 - antibody + FITC-peptide + 2% 
chaps buffer). Peak 4 represents Free-FITC-peptide.  
4.1.4 Analysis of PrPC expression by Western blot 
We further analyzed the PrPC expression by the Western blots and observed up-
regulation of the PrPC expression in female wild type mice liver but only in the aging 




mice (14 months) but the expressional regulation of PrPC in the 3 and 9 months aged 
mice liver using Western blot was absent, due to low sensitivity of Western blot  
 
Fig. 10. PrPC expression in liver: PrPC expression in female (peak 1) and male (peak 2) in 
3 (A), 9 (B) and 14 months old (C) by Capillary electrophoresis (CE). Peak 3 and 4 
represents free FITC-peptide and antibody control (FITC-peptide + Antibody). There was age 
and gender dependent significant regulation of PrPC expression (D), represented by relative 




differences in Area/100000×Ratio by CE (Calculations in Index-Table-5), (E) and (F), by 
Western blot.  
technique (Fig. 10E and 10F), which clearly indicated an advantage to use CIE for 
the measurement of the minutely expressed proteins in the tissues. 
4.2 Age and gender specific differential proteome analysis in PrPC 
knockout mice liver  
As we showed an age and gender dependent regulation of PrPC expression in the 
liver of wild type mice, therefore, this observation confirmed our first hypothesis that 
aging could be associated with up-regulation of PrPC expression. Our second 
hypothesis was the possibility of liver pathology in the PrPC knockout mice liver due 
to reported role of PrPC in hepatic stellate cells activation. The third hypothesis was 
based on proteomics and genomics reports in the brain of PrPC knockout mice. 
Therefore, we were expected to get regulation of liver functions linked with the 
hepatic stellate cells activation such as liver disease and also regulation of tau/ptau 
dependent cytoskeleton functions in the liver of PrPC knockout mice. 
4.2.1 Two-dimensional (2D) gel electrophoresis 
To understand age and gender dependent altered expression of PrPC and to prove 
our further hypothesis, we used liver tissue from Zurich I PrPC knockout mice. 
Hence, we performed 2D gel electrophoresis based proteomics approach to get the 
robust functional networks. We used liver samples from 3, 9 and 14 months old age 
liver with both genders. In total, 48 gels (17 cm width) with well separated spots were 
obtained by 2D gel electrophoresis. Images of each gel were taken at 300 dpi using 
Canon LiDE 110 scanner (Fig.11) which was used for further software analysis. 
Using Delta2D’s 100% spot matching approach, 3035 protein spots were detected on 
liver 2D gel patterns and each spot was identified with multiple set of proteins. 27 
spots were regulated in the liver of PrPC knockout mice compared to the wild type 
mice which constituted 64 proteins in total (Table 3). 
In total, 19 proteins were regulated in the liver of 3 and 14 months old PrPC knockout 
male mice as compared to the wild type while there was no regulation found in the 9 
months male group (Fig. 12). 45 proteins were found to be regulated in the liver of 3, 
9 and 14 months old PrPC knockout female mice as compared to the wild type (Fig. 
13).    






Fig. 11. 2D gels: Gel images from 3, 9 and 14 months old (PrPC knockout and wild type 
mice liver) age with male and female groups were analyzed by Delta2D DECODON 
software. 
 




Fig. 12. 2D gel maps of male liver samples: 3 months; wild type (Panel A), PrPC knockout 
(Panel B), 9 months; wild type (Panel C), PrPC knockout (Panel D), 14 months; wild type 
(Panel E), PrPC knockout (Panel F) obtained by silver staining of 2D gels. Densitomeric and 




statistical analysis revealed the up-regulation of one spot and down-regulation of 9 spots. No 
protein was significantly regulated in 9 months male group. 
Fig. 13. 2D gel maps of female liver: 3 months; wild type (Panel A), PrPC knockout (Panel 
B), 9 months; wild type (Panel C), PrPC knockout (Panel D) and 14 months; wild type (Panel 




E), PrPC knockout (Panel F) obtained by silver staining of 2D gels. Densitomeric and 
statistical analysis revealed the of upregulation of 9 spot and down-regulation of 8 spots. 
Table 3 – Detailed list of statistically significant (P value ≤ 0.05) dataset from mass 
spectrometry analysis: List included regulated proteins from 3, 9 and 14 months old in the 
PrPC knockout mice liver as compared to the wild type (No proteins were found regulated in 
9 months male PrPC knockout mice liver). The list is arranged by the protein name with 
accession numbers and molecular mass with their unique iso-electric pH (pI). Protein 














Male Mice                               PrPC knockout vs Wild type  (3 months) 
1 Actin, cytoplasmic 1  P60710 41.737,80 15.70% 23 2.48 ↓ 0.01 5.29 








Q9Z1Z2 38.443,30 40.30% 26 1.53 ↓ 0.014 4.99 
5 Regucalcin  Q64374 33.407,10 56.90% 155 1.59 ↓ 0.031 5.16 
6 Thioredoxin-like 
protein 1  
Q8CDN6 32.237,40 45.70% 34   4.84 




Q91ZA3 79.921,90 17.70% 17 1.58 ↓ 0.04 6.04 
PrPC knockout vs Wild type  (14months) 
9 U5 small nuclear 
ribonucleoprotein 200 
kDa helicase  





Q91WS4 39.871,70 44.60% 36   6.10 
11 Pre-mRNA-
processing-splicing 
Q99PV0 273.624,50 6.85% 24   8.95 










Q9D6J6 27.285,50 49.20% 24   5.31 




O08810 109.362,90 16.10% 22   4.86 
14 Transaldolase  Q93092 37.388,50 24.30% 18   6.57 
15 3-mercaptopyruvate 
sulfurtransferase 





ase, mitochondrial  
O35459 36.119,20 45.00% 54   6.01 
17 3-hydroxyanthranilate 
3,4-dioxygenase  
Q78JT3 32.804,30 54.90% 48   6.10 
18 L-xylulose reductase  Q91X52 25.745,40 34.00% 16   6.83 

















Female mice                      PrPC knockout vs Wild type  (3 months) 
20 Isocitrate 
dehydrogenase 




18   5.59 
21 Calponin-3  Q9DAW9 36.429,60 33.60
% 
17   5.46 
22 Annexin A5  P48036 35.754,20 59.90
% 
182 2,16 ↓ 0.006 4.82 




12   4.91 




24 Alpha-soluble NSF 
attachment protein 
Q9DB05 33,190.8 70.5% 146 2.14 ↓ 0.013 5.30 
25 40S ribosomal protein 
S3a  
P97351 29,885.3 40.2% 25   9.75 
26 Cathepsin Z  Q9WUU7 33,996.3 20.6% 22   5.31 

















48   6.10 
31 L-xylulose reductase  Q91X52 25.745,40 34.00
% 
16   6.83 
32 Vacuolar protein 
sorting-associated 
protein 29  
Q9QZ88 20.496,10 44.50
% 






15   6.47 
34 14-3-3 protein 
gamma 
P61982 28,303.1 36.0% 21 2.66 ↑ 0.017 4.80 




48 2.07 ↑ 0.004 5.35 
36 Ferritin heavy chain P09528 21.067,20 31.30
% 
16   5.53 





30 2.05 ↓ 0.039 5.94 
38 Aminoacylase-1  Q99JW2 45.781,20 35.30
% 
26   5.89 
39 Leukocyte elastase 
inhibitor A  
Q9D154 42.576,60 44.10
% 





14   6.60 


























16   6.83 














28   7.68 

















  6.54 
 
                 PrPC knockout vs Wild type  (14 months)  




507 1,56 ↓ 0.029 5.44 
50 Lamin-B2  P21619 67.318,50 49.30
% 
64   5.36 
51 Heat shock cognate 
71 kDa protein 
P63017 70.872,80 29.60
% 
25   5.37 
52 Glycerol kinase Q64516 61.228,10 27.00
% 






15   5.64 
 Protein disulfide-
isomerase A4  
P08003 71.984,40 24.30
% 
19   5.06 




13 4.96 ↓ ≤ 
0.001 
5.24 
55 Leukocyte elastase Q9D154 42.576,60 44.10 59 2.23 ↑ 0.012 5.82 















12   7.11 
58 Apolipoprotein A-I  Q00623 30.615,30 16.30
% 
6   5.31 
59 Amine 
sulfotransferase  








P14152 36,512.1 43.7% 29   6.16 
62      10.94 ↑ 0.031  
63 Propionyl-CoA 
carboxylase alpha 
chain, mitochondrial  
Q91ZA3 79.921,90 17.70
% 
17 5.27 ↓ 0.003 6.04 
64 Putative hydrolase 
RBBP9  
O88851 20,911.8 19.4% 13   5.62 
4.3 Bio-informatics based functional network analysis 
As described in methods part that IPA is a bio-informatics tool aimed to analyze the 
complex proteomics dataset to build functional networks based on the literature 
information stored in IPKB from a given set of statistical significant dataset.    
We used the proteomics dataset with their accession numbers and fold change (up or 
down-regulated in PrPC knockout mice in comparison to the wild type mice) to 
analyze with the IPA inguenuity software. The proteomics dataset of male and female 
groups were combined together to build IPA networks because of the less number of 
proteins in the male group. Number of proteins in 3 , 9 and 14 months old groups 
were not enough to built a significant network by IPA analysis, so we also combined 
proteomics dataset from all the age groups into one set and analysis was performed 
to find the functional networks relevant to the PrPC function.    




4.3.1 IPA analysis (Liver as a reference tissue)  
The IPA ingenuity software gave three pathways with three different functional 
networks (Fig no. 14) 
Network1: Gastrointestinal Disease, Hepatic System Disease, Liver Steatosis 
(Index – Table 1).  
Network2: Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry 
(Index – Table 2).  
Network3: Cellular Function and Maintenance, Cellular Growth and Proliferation, 
Cellular Movement (Index – Table 3).  
We obtained a very diverse forms of functional networks, network 1 had the highest 
score, which is associated with the liver steatosis and hepatic system disease. Liver 
steatosis is also known as fatty liver disease, is a reversible condition in which large 
vacuoles of triglycerides with increased density, gets deposited in the liver cells. In 
addition, IPA functional networks also indicated the regulation of lipid metabolism 
(Network2) in the liver of PrPC knockout mice as compared to the wild type mice. 
Next step was to examine if the liver has any disease pathology including fatty liver 
disease as predicted by IPA. First, we intended to examine the fat content in the liver 
and perfomed biochemical measurment of triglyceride levels in the liver of PrPC 
knockout mice as compared to the wild type mice followed by Sudan III staining to 
examine the number and intensity of fat globules in the liver of PrPC knockout mice.  





Fig. 14. IPA software Network 1 - Functional network analyzed by comparing the 
proteomics dataset of PrPC knockout mice liver and wild type (both genders and all age 
groups). The network was associated with gastrointestinal disease, hepatic system disease, 
liver steatosis (Detail, Index – Table 1) 
4.3.1.1 Triglyceride content:  
Triglyceride content was measured in the liver of PrPC knockout mice as compared 
to the wild type. We found significant up-regulation of triglyceride content (mg/dl) in 
14 months old only which indicated the presence of fatty liver disease in the liver of 
aging PrPC knockout mice (Fig.15).  




Fig. 15. Quantitative measurement of triglyceride content in the liver tissue: (A) Liver 
tissue of PrPC knockout mice (KO) showed significnatly higher amount of triglycerides 
content as compared to the wild type (W) at old age (14 months). (B) No significant 
differences in the triglycerides content was observed in the liver of PrPC knockout mice as 
compared to the wild type in 9 months old age group.   
4.3.1.2 Fat globules in PrPC knockout mice liver 
Further, we investigated the fat content by Sudan III staining in the liver of 14 months 
old  mice. We detected fat globules in PrPC knockout mice liver, which confirmed the 
presence of liver steatosis in the liver of PrPC knockout mice (Fig.16). Notably, fat 
globules were almost negligible in the liver of male PrPC knockout mice while some 
fat rich specific cells (Fig.17) were present in both male and female PrPC knockout 
mice liver as compared to the wild type. It is evident that these specific fat laden cells 
could be hepatic stellate cells (HSCs) because HSCs are known to be rich in fat and 
it needs specific marker stainings for further confirmation.   
4.3.1.3 Liver pathology:  
Liver steatiosis could be associated with the increased cell death due to apoptosis 
and inflammation, which are the indicators of non-alcoholic steatohepatitis (NASH), 
an advanced stage of fatty liver disease (Wieckowska et al., 2006). First, we 
investigated, if there was any evidence of apoptosis in the liver of PrPC knockout as 
compared to the wild type. The imbalance of pro-apoptotic protein Bax and anti-
apoptotic protein Bcl2 has been reported to contribute to hepatocyte apoptosis during 
the pathogenesis of NASH (Wang et al., 2008). 
 





Fig. 17. Liver disease pathology (female): Liver tissue stained with Sudan III staining 
indicating a higher fat content in the liver of 14 months old PrPC knockout mice (A, B and C) 
as compared to the wild type mice (D, E and F), where no pathological phenotypes were 
observed. (G) indicating a magnified image of specfic fat rich cell. Nucleus was stained with 
hematoxylin. Scale bar – 20 µm 





Fig. 17. Liver disease pathology (Male): Liver tissue stained with Sudan III staining 
indicating a higher fat content in the liver of 14 months old PrPC knockout mice (A, B and C) 
as compared to the wild type mice (D, E and F), where no pathological phenotypes were 
observed. (G) indicating a magnified image of specfic fat rich cell. Nucleus was stained with 
hematoxylin. Scale bar – 20 µm 
Therefore, further we analyzed the expression of Bax and Bcl2 in the liver of PrPC 
knockout female mice by Western blot because severe fatty liver disease pathology 
was observed only in the female group. We observed an increased Bax to Bcl2 ratio 
(Fig.18A and 18B), which indicated that the liver steatosis might be associated with 
apoptosis in the liver of PrPC knockout female mice. It evidenced the presence of 
NASH, an advanced stage of fatty liver disease. 




Fig. 18. Bax/Bcl2 protein expression in 14 months old female mice liver: (A); Western 
blot analysis shows the down-regulation of Bcl2 expression in the liver of PrPC knockout 
mice in comparison to the wild type mice, while the expression of Bax was not regulated in 
either groups. (B); Bar graph shows the significant up-regulation of Bax to Bcl2 ratio in the 
liver of PrPC knockout mice (KO) as compared to the wild type mice (W).  
4.3.2 IPA analysis (Brain as a reference tissue) 
As mentioned earlier, most of the PrPC functional studies with Zürich I model has 
been done in the brain only. Therefore, the networks linked with PrPC function were 
totally undiscovered in the liver. Hence, we decided to analyze the liver proteomics 
dataset by IPA software again but selected other tissues such as brain as well, which 
provided a better opportunity to get functional networks with broader literature 
information stored in IPKB. Results revealed the involvement of 8 different functional 
networks (Index – Table 4), which were linked to the cellular development, cell 
signaling, cellular growth and proliferation. Interestingly, the investigation of networks 
built with reference tissue as brain revealed the regulation of many proteins such as 
cytoskeleton associated microtubule associated protein tau (MAPT) which has been 
linked with alzheimer disease pathways. The relation of PrPC and tau function has 
already been described in the brain and also in the context of neurodegeneration. In 
addition, recent studies from our group using PrPC knockout mice, has described the 
role of PrPC in regulating the tau and ptau expressions in the different regions of 
brain (Schmitz  et al., 2014). The previous proteomics and genomics reports in the 
brain of PrPC knockout mice has also linked PrPC functional networks with alzheimer 
disease pathways (Benvegnù et al., 2011). Our proteomics dataset also showed the 
down-regulation of cytoskeleton proteins like actin – cytoplasmic, actin - aortic 
smooth muscle (number 1 and 54, Table 3) in the liver of PrPC knockout mice. 
Further, as we showed liver steatosis in the liver of PrPC knockout mice and 
interestingly liver steatosis has also been reported to be associated with the 




increased expression and formation of cytoskeleton protein aggregates of keratins 
and tau (Zatloukal et al., 1995). Authers also suggested that disturbance of 
cytoskeleton may be linked to the accumulation of triglycerides due to defects in 
molecular transport.  
Therefore, in order to understand the link between age related pathological outcome 
in liver and alteration of cytoskeleton function, we analyzed the tau protein functional 
regulation in the liver of PrPC knockout as compared to the wild type. We analyzed 
the expression of tau and its phosphorylated form (ptau-199) in 3, 9 and 14 months 
old group. Further, we analyzed enzymes expression levels which have already been 
described to be involved in regulating tau phosphorylation.   
4.3.2.1 Altered Tau/Ptau expression in mice liver by Western blot 
The expression of tau decreased with age and was comparatively low in the liver of  
14 months old age mice as compared to 3 and 9 months in both PrPC knockout as 
well as wild type mice. In 14 months, tau expression was up regulated in the PrPC 
knockout mice compared to the wild type but results were not significant (Fig. 19A 
and 19B). As there were no significant differences between male and female groups 
in the tau expression, therefore we combined the densitometric quantifications 
(Fig.19B). The expression of ptau was increased significantly with the age and was 
found to be maximum in the old age in both male and female wild type mice liver. 
Further, in comparison to the wild type we found significant down-regulation of ptau 
expression in the liver of aging PrPC knockout mice as compared to the wild type 
mice (Fig. 19A and 19C). Although not significantly, expression of ptau in male 
appears to be lower than female in the liver of PrPC knockout mice and there was no 
such regulation in the wild type mice.     
 





19. Tau and Ptau expression: (A); Western blot analysis shows the expression of tau/ptau 
in the liver of 3, 9 and 14 months old (3m, 9m and 14m) male and female PrPC knockout 
mice (KO) as compared to wild type (W) mice. There was age dependent decrease of tau 
expression from 3 to 14 months old in both PrPC knockout and wild type mice liver. The 
expression of tau in the liver of 14 months old PrPC knockout was up-regulated as compared 
to the wild type, although results were not significant. The expression of ptau was 
significantly down-regulated in the liver of 14 months old PrPC knockout mice as compared 
to the wild type. (B) and (C); Densitometry quantification of tau/ptau expression bands show 
the significant fold change expressions of tau and ptau in the PrPC knockout mice liver as 
compared to the wild types group respectively.  
4.3.2.2 Altered Tau/Ptau expression in mice liver by immunofluorescence 
Further, we performed the immunofluorescence experiments to confirm the 
expressional regulation of tau/ptau. We found age dependent decrease of tau 
expression from 3 to 9 months in both wild type and PrPC knockout mice liver (Fig. 
20M, 20N, 20O, 20P) while expression of tau is significantly up regulated in the liver 
of 14 months old PrPC knockout mice as compared to the wild type (Fig. 20R and 
20Q). A similar trend has been observed in the Western blot experiments (Fig. 19A 
and 19B) but the results were not significant. So, the results from 
immunofluorescence has a similar expressional regulation as observed in Western 
blots. Further, there was down-regulation of ptau expression in the liver of PrPC 




knockout mice as compared to the wild type in 9 and 14 months old group (20I, 20J, 
20K, 20L) while there was not much differences in signal in 3 months (Fig. 20G and 
20H). Therefore, the results were correlated to the ptau expression in the 14 months 
old Western blot experiments (Fig. 19C). 
Fig. 20. Ptau/Tau expression in 3, 9 and 14 months old age mice: Panel 3 shows an age 
dependent decrease of tau expression from 3 to 9 months old in both PrPC knockout (N, P) 
and wild type mice liver (M, O). The expression of tau in the liver of 14 months old PrPC 
knockout (R) was significantly up-regulated as compared to the wild type mice (Q). Panel 2 
shows the expression of ptau in 3 (G), 9 (I) and 14 months old (K) wild type mice liver and 
PrPC knockout mice liver (H, J, and L). The expression of ptau was significantly down-
regulated in the liver of 9 and 14 months old PrPC knockout mice (J, L) as compared to the 
wild type mice (I, K). Panel 4 shows the co-localization of Tau and ptau expression and 
nucleus was stained with DAPI (panel 1).   




4.3.2.3 Cyclin dependent kinase 5 (CDK5)/p25 fragment expression by Western 
blot 
           Cdk5 is known to catalyze the phosphorylation of tau protein. Its activation depends 
on its interaction with p25 fragment, so along with expression of Cdk5 itself, the 
expression p25 dictates the activation of Cdk5. We analyzed its expression levels in 
the 14 months group. We found an up-regulation of p25/Cdk5 in the liver of PrPC 
knockout female, but no regulation in the male group (Fig. 21). 
 
Fig. 21. Cdk5/p25 expression: (A) and (B); Western blot analysis shows the expression of 
Cdk5 and p25 in the liver of 14 months old PrPC knockout female (F KO) and male (M KO) 
mice as compared to the wild type female (F W) and male mice (F W) respectively. (C) and 
(D); Densitometry quantification of Cdk5/p25 expression shows the significant up-regulation 
of p25 expression in the liver of female PrPC knockout mice (14 months old) compared to the 
wild type.    
4.3.2.4 Gsk3Beta/P-gsk3Beta expression by Western blot 
We further analyzed the enzyme expressional regulations of gsk3beta and its 
phosphorylated (active -Tyr216) form, pgsk3beta in the 14 months old group. The 
expression of gsk3beta was down-regulated in the liver of PrPC knockout male mice 
as compared to the wild type (Fig. 22A and 22C). Gsk3beta enzyme is known to be 




activated by the phosphorylation of Tyr216 residue. Therefore, the amounts of 
pgsk3beta (phosphorylation at Ty216) determines the activation of gsk3beta. 
Therefore, we further analyzed the expression of pgsk3beta (at Tyr216) by using 
pgsk3beta antibody which was specific for the phosphoTyr216 epitope. The 
expression of pgsk3beta was significantly down-regulated in the liver of aging PrPC 
knockout mice (14 months) as compared to the wild type mice (Fig. 22B and 22D). It 
showed that  pgsk3beta might be involved in the regulation of tau phosphorylation, as 
we have observed the similar down-regulation of ptau expressions by Western blot 
as well as by immunofluorescence (Fig. 19C, 20L and 20K). 
Fig. 22. Gsk3beta/p-gsk3beta expression: (A) and (B); Western blot analysis shows the 
expression of gsk3beta and p-gsk3beta in the liver of 14 months old PrPC knockout female 
(F KO) and male (M KO) mice as compared to the wild type female (F W) and male mice (F 
W) respectively. (C) and (D); Densitometry quantification of gsk3beta/pgsk3beta expression 
shows the significant down-regulation of pgsk3beta in the liver of male and female PrPC 
knockout mice (14 months old) as compared to the wild type.  





Liver is physiologically and functionally linked with all other organs of the body and is 
vital for the survival. Although few reports have been published to analyze the 
expression of PrPC in liver, but surprisingly, only two reports have been published till 
date to understand the role of PrPC in liver (Raeber et al., 1999, Ikeda et al., 1998). 
To characterize the function of PrPC in the liver, first challenge was to obtain the 
expressional profile of PrPC. As mentioned previously, the expression of PrPC in the 
liver has been reported to be very low, may be therefore all of the previous reports 
were based on embryonic, young and adult mice (Ford et al., 2002, Horiuchi et al., 
1995; Moudjou et al., 2001; Peralta et al., 2012). Therefore, we tried to obtain the 
detailed expressional profile of PrPC from adult to aging, male and female wild type 
mice liver. To improve the detection of PrPC, we employed a highly sensitive method 
based on capillary electrophoresis (CE) along with the standard techniques. 
Furthermore, altered proteome associated with PrPC expressional regulation was 
uncovered by using 2D gel electrophoresis which was followed by bioinformatics 
software based functional analysis. 
5.1 PrPC expressional profile in liver 
The detection of PrPC by capillary electrophoresis (CE) immunoassay has already 
been demonstrated in the previous reports (Yang et al., 2005). Additional 
advancement of the method by the use of carboxymethyl-β-cyclodextrin (CM-β-CD) 
aided separation, PrPC specific FITC-peptide and PrPC specific rabbit Rb70 have 
provided further improvements to detect the subtle changes in PrPC expression. The 
sensitivity of the method (1pg) has already been reported to be much higher 
(approximately 10 fold) than the standard techniques such as Western blot.   
Interestingly, the higher expression of PrPC in the old age compared to the young 
and adult age mice has already been described in the brain (Williams et al., 2004) as 
well as in the human peripheral blood leukocytes (Politopoulou et al., 2000). The 
reports have linked the higher expression of PrPC in the old age to increase in 
oxidative stress as a part of aging mechanism (Gasperini et al., 2014).  Therefore, in 
order to understand the role of PrPC during aging in liver, it seems critical to measure 
its expressional profile from young adult to aging mice. We have shown the higher 
expression of PrPC in the 14 months old mice by Western blot. Further, the 




expression of PrPC was higher in the liver of female wild type mice as compared to 
the male. But we could not find any subtle differences in the adult (3 months) or 
advanced adult age (9 months) by using Western blot technique. Interestingly, by CIE 
we found similar gender dependent up-regulated expression of PrPC in the liver of 9 
months old female wild type mice. Further, there was an age dependent regulation of 
PrPC expression in the liver of 14 months old wild type mice as compared to the 3 
and 9 months. Furthermore, the PrPC expression at the transcriptional level showed 
a similar age and gender dependent expression of PrPC mRNA by qPCR. 
The sCJD disease has been reported to occur in humans in the 7th decade and its 
prevalence in women is higher than in males across the countries (Appleby et al., 
2007). The link between the amount of PrPC and the susceptibility of the disease is 
not fully understood. There are some experiments that demonstrate that the 
incubation period of the disease might depend on the levels of PrPC in the peripheral 
tissues due to the fact that PrPC/PrPSc molecules may potentially be released into 
the extracellular environment (Fevrier et al., 2004, Molloy et. al., 2005). Hence, we 
hypothesized that the higher expression of PrPC during aging in brain and peripheral 
tissues such as liver along with the effect of gender might be important factors to 
dictate the susceptibility and incubation period of the disease.   
Hence, with the help of CIE and Western blotting, we showed a higher expression of 
PrPC in the females and in addition, the significant up-regulation of PrPC in the aging 
wild type mice liver as compared to the 3 and 9 months. It could be associated with 
the role of PrPC during aging and oxidative stress. Therefore, the up-regulation of 
PrPC in the liver of aging wild type mice might be linked with the activation of hepatic 
stellate cells (HSCs) because the activation of HSCs has already been reported to be 
associated with the up-regulation of PrPC expression (Ikeda et al., 1998).  
5.2 Functional proteome analysis  
To understand the role of PrPC in liver in detail, we used 2D gel based proteomics 
approach. The proteins which were differentially regulated (Proteomics dataset) in 
the liver of PrPC knockout mice as compared to the wild type was classified by based 
on their functions (Index – Fig. 1). The clusters of proteins with highest percentage 
(24%) belong to protein/Amino acid metabolism, followed by energy (17%) and lipid 
metabolism (11%), mRNA splicing/gene regulation (9%) and cytoskeleton (9%).   




5.2.1 Protein/Amino acid metabolism  
This group constituted the highest percentage of total proteins (24%). The 
protein/amino acid metabolism is a set of critically regulated biochemical reactions, 
which involve the synthesis and breakdown of protein/amino acids to maintain the 
constant turnover rate. Liver tissue is of central importance because large numbers of 
physiologically important proteins are synthesized in the liver and secreted into 
circulation. Among various proteins that have been found in this category, following 
were of particular interest in context of defining the PrPC function:   
5.2.1.1 3-hydroxyanthranilate 3, 4-dioxygenase (HAAO-3)  
This enzyme is the part of tryptophan metabolism which catalyzes the conversion of 
3-hydroxyanthranilate into quinolinic acid (QUIN) from 3-hydroxyanthranilic acid. The 
quinolinic acid may serve as a precursor for NAD(+) and has also been described as 
a neurotoxic compound (Sahm et al., 2013). The reports have suggested that the 
secretion of quinolinic acid from liver into circulation might further be passed through 
blood brain barrier (Basile et al., 1995). Further, quinolinic acid mediated toxicity has 
also been described to be involved in the neurodegeneration (Sahm et al., 2013). In 
the differential proteome dataset (Table 3) of both male and female group, we have 
observed the up-regulation of HAAO-3 in the liver of PrPC knockout mice as 
compared to the wild type. The above evidences showed that the up-regulation of 
HAAO-3 consequently may cause the accumulation of toxic quinolinic acid in the 
liver. Further, it might be linked with its levels in the brain of PrPC knockout mice 
which still needs to be determined. In addition to its role in tryptophan metabolism, 
the regulation of HAAO-3 in PrPC knockout mice liver has highlighted a possible 
insight into role of PrPC in liver-brain functional axis in relevance to the prion 
diseases.   
5.2.1.2 Capthepsin Z 
Cysteine cathepsins are the group of lysosomal proteases, which degrade 
polypeptides with their specific mechanisms (Wiederanders et al., 2003). Cathepsin Z 
is a carboxypeptidase which has the specificity to a single catalytic site with cysteine 
thiol group (Guncar et al., 2000). The role of cathepsins in autocatalytic conversion of 
normal cellular PrPC into protease K resistant PrPSc in scrapie-infected Neuro2a 
cells has already been described (Zhang et al., 2003). Further, the up-regulation of 
various cathepsins subtypes including cathepsin z have been reported in scrapie-




infected mice brains (booth et al., 2004). However, we found 2.14 fold down-
regulation of cathepsin z in the 3 months PrPC knockout mice liver as compared to 
the wild type. Although needs further investigations, however above evidences 
showed that PrPC might be involved in regulating the expression of cathepsins in 
mice liver, which could further be associated with the regulation of prion infection or 
its sporadic conversion into PrPSc.  
5.2.2 Bioenergetics/Glucose metabolism 
This group constituted 17% of the total proteins and is considered as an important 
group because all the cellular processes are linked with bioenergetics. The important 
proteins of this group included: NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial, transaldolase, L-xylulose reductase, isocitrate dehydrogenase [NAD] 
subunit alpha, mitochondrial, L-xylulose reductase, 39S ribosomal protein L12, 
mitochondrial, sorbitol dehydrogenase, alcohol dehydrogenase class-3 and malate 
dehydrogenase.  
The key enzymes involved in bioenergetics are the components of NADH 
dehydrogenase [ubiquinone], isocitrate and malate dehydrogenase. All are the 
important mitochondrial enzyme components which have been associated with 
electron transport chain and citric acid cycle.   
These enzyme components were found to be down regulated in the liver of PrPC 
knockout mice as compared to the wild type mice. In addition, there was down-
regulation of mitochondrial ribosomal protein 39S ribosomal protein L12 protein. 
Interestingly, the alterations in the expression of mitochondrial proteins, DNA, RNA 
and lipid content due to increase in oxidative stress have already been described 
(Crawford et al., 1996, Fariss et al., 2005). Further, the down-regulation of 
mitochondrial RNA levels have been reported as a response mechanism in liver cells 
to protect against oxidative stress (Crawford et al., 1996). Moreover, the role of PrPC 
against oxidative stress has already been very well documented from the studies in 
neuronal tissue (Brown et al., 1999). The above evidences showed that PrPC might 
have an important role in modulating the mitochondrial activity in response to 
oxidative stress in liver.   




5.2.2.1 Transaldolase  
It is a key enzyme of reversible non-oxidative branch of pentose phosphate pathway, 
which regulates the reduced state of glutathione (GSH) by regulating the NADPH 
levels. Prnp knock down based approach in human embryonic kidney (HEK), has 
reported the down-regulation of transaldolase expression (Ramljak et al., 2007). An 
additional report showed that the down-regulation of transaldolase in jurkat human T 
cells resulted into reduced apoptosis and increased levels of glutathione (Banki et al., 
1996). Further, a study performed in cirrhotic liver patients has reported the 
increased cell death due to the deficiency of transaldolase (Perl et al., 2007). In 
concordance with the previous reports, we have observed similar down-regulation of 
transaldolase in the liver of PrPC knockout male as compared to the wild type. It 
showed an important role of PrPC in maintaining the levels of glutathione and also 
regulating the apoptosis. The elucidation of detailed pathways involved, needs further 
investigation.  
5.2.2.2 Malate dehydrogenase (MDH)   
Malate dehydrogenase is an enzyme of citric acid cycle, which catalyzes the 
reversible conversion of malate into oxaloacetate. The regulation of MDH has critical 
biological significance because several catabolic pathways of macromolecules such 
as carbohydrates, lipids and proteins converge on the citric acid cycle (TCA) to 
produce ATP. A report has shown the down-regulation of MDH in the brain of sCJD 
patients (Xiang et al., 2005). Further, the proteomics dataset from our study also 
showed the down-regulation of malate dehydrogenase in the liver of 14 months old 
PrPC knockout female mice. It further supports that the loss of PrPC function due to 
its conversion into PrPSc in sCJD might be linked with the down-regulation of energy 
metabolism as a part of the disease mechanism.   
5.2.3 Lipid metabolism  
This group constituted the 11 % of the total PrPC dependent regulated proteins. 
Proteins included in this group included:  
5.2.4 Farnesyl pyrophosphate synthase  
It is an important enzyme of lipid/steroid metabolism, which catalyzes the synthesis of 
farnesyl diphosphate (FPP) and latter acts a precursor for many metabolites 
including, dolichols, sterols, ubiquinones and carotenoids. In addition, the farnesyl 




diphosphate also acts as a substrate for farnesylation and geranylgeranylation of 
proteins. We have found the down-regulation of FPP synthase in the liver of 3 
months PrPC knockout mice as compared to the wild type. This showed a role of 
PrPC in regulating the cholesterol levels. Recently, the depletion of cholesterol from 
the membrane lipid rafts has been demonstrated as a causative factor to the 
increased susceptibility of PrPC misfolding (Sarnataro et al., 2004). The down-
regulation of FPP synthase in the liver of PrPC knockout suggests that PrPC may 
regulate cholesterol synthesis and could be linked with the correct folding of the PrPC 
protein itself. In conclusion, according to the loss of function hypothesis, the 
conversion of PrPC into PrPSc might be linked with the cholesterol metabolism and 
modulating the further susceptibility of PrPC misfolding.   
5.2.5 Apolipoprotein A-I (ApoA-I) 
It is another protein linked with the cholesterol metabolism. 14 months old PrPC 
knockout mice liver has shown an up-regulation of ApoA-I (proteomics dataset). 
ApoA-I is required for the reverse transport of cholesterol from the body into the liver 
for excreting out of the body (Zhang et al., 2003). Therefore, the up-regulation of 
Apolipoprotein A1 in the PrPC knockout mice might be involved in cholesterol 
depletion or deficiency and as described earlier, which has been a crucial factor for 
the proper folding of PrPC within the lipid rafts.   
Physiologically, liver critically regulates the cholesterol levels of all other organs. 
PrPC seems to possess physiological importance by regulating the enzymes and 
transport proteins of cholesterol metabolism in the liver.  
5.2.6 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase(DI) 
It is an enzyme of beta-oxidation of fatty acids, which catalyzes the isomerization of 
3-trans,5-cis-dienoyl-CoA to 2-trans,4-trans-dienoyl-CoA. Proteomics dataset has 
shown the up-regulation of DI in all three age groups of PrPC knockout male mice 
liver. Therefore, the up-regulation of DI may trigger higher FFAs beta oxidation and 
subsequently, the increased generation of reactive oxygen species (ROS) in the liver 
diseases such as NASH (Sanyal et al., 2001). The up-regulation of DI indicated that 
the liver of PrPC knockout mice might have higher oxidative stress due to the 
increased beta oxidation of fatty acids. It showed an antioxidant role of PrPC in the 
liver, which has been in correlation with the previous discussion.  




5.2.7 mRNA splicing/gene regulation  
We have obtained a cluster of proteins (9% of the dataset), which are the 
components for mRNA splicing and all proteins were regulated in the male group. 
Proteins were down regulated in the liver of PrPC knockout mice compared to the 
wild type which revealed an important function of PrPC in regulating the gene 
expression at transcriptional level. Proteins classified to this group were: Serine-
threonine kinase receptor-associated protein, U5 small nuclear ribonucleoprotein 200 
kDa helicase and Pre-mRNA-processing-splicing factor 8, a U5 small nuclear 
ribonucleoprotein component.   
5.2.7.1 Serine-threonine kinase receptor-associated protein (STRAP) 
It is ubiquitously expressed in all the mouse tissues with the highest expression in the 
liver and testes but it is less abundant in the spleen (Kashikar et al., 2012). It has 
been involved in TFG-β signaling, mRNA transport, PDK signaling and U SnRNA 
assembly. We have found the down-regulation of STRAP in the liver of 3 months old 
PrPC knockout male mice. Although, the implication of STRAP in diverse functions 
reflects a role of PrPC in the cell proliferation, gene regulation and PKB/AKT 
signaling but the elucidation of the detailed mechanisms needs further investigation.   
5.2.7.2 U5 small nuclear ribonucleoprotein 200 kDa helicase  
It is an enzyme associated with the tri-snRNP RNA helicase that plays a role in the 
pre-mRNA splicing as a component of U5 snRNP and U4/U6-U5 tri-snRNP 
complexes. One study described that the dominant negative and the transient 
expression of this gene in the mammalian cell causes defects in the cell cycle 
(Ehsani et al., 2013). We have observed the down-regulation of this protein in the 
liver of 14 months old PrPC knockout male as compared to the wild type. Hence, 
PrPC appears to be involved in the cell cycle and the cell proliferative pathways.  
5.2.7.3 Pre-mRNA-processing-splicing factor 8  
Pre-mRNA-processing-splicing factor 8 is known for its role in ordering the 
assemblies of spliceosomal proteins and snRNAs. The mutation of Prpf8 factor 
affects the splicing, cell survival and myeloid differentiation (Keightley et al., 2013). 
We have found the down-regulation of Prpf8 in the 14 months old PrPC knockout 
male mice as compared to the wild type.  




5.2.7.4 116 kDa U5 small nuclear ribonucleoprotein component  
It is another component of U5 snRNP and U4/U6-U5 tri-snRNP complexes. It has 
been observed to be down-regulated in the liver of 14 months old PrPC knockout 
male in comparison to the wild type.  
In conclusion, we have found a cluster of proteins which are associated with mRNA 
splicing and found to be down-regulated in the liver of PrPC knockout mice liver as 
compared to the wild type. The defects associated with the mutations of these 
splicing gene components have been linked with the cell cycle and proliferation. The 
above evidences indicated that aging PrPC knockout mice liver might have altered 
regulation of liver cell proliferative pathways which could be in response to the liver 
injury that we have reported in the same 14 months PrPC knockout group due to liver 
steatosis. It might also directly be linked the function of PrPC, because the role of 
PrPC in cell growth and proliferation is already known (llorenz et al., 2013). 
Therefore, the above evidences showed that PrPC play an important role in cell 
proliferation in the aging mice liver. To understand the pathways involved needs 
further investigations. 
5.2.8 Structural/Cytoskeleton  
This group constitutes the 9% of the total PrPC dependent regulated proteins. The 
selected proteins in this group include:  
5.2.8.1 Annexin 5 (Anxa V) 
Annexin 5 belongs to the family of calcium-dependent phospholipid binding proteins. 
Although the precise function of this protein is unknown, but it is believed to inhibit 
the phospholipase A2 and protein kinase C enzyme activities, calcium channel 
activity, involved in inflammation, cellular signal transduction and differentiation 
(Hammill et al., 1999, Reutelingsperger et al., 1997). It has been demonstrated that 
the overexpression of PrPC in the HEK293 cells results into the up-regulation of Anxa 
V (Ramljak et al., 2007) and another study based on gene expression profiling 
showed its up-regulation in frontal cortex of sporadic CJD patients (Xiang et al., 
2005). In liver, its role has been illustrated against ischemia and reperfusion injury 
following the rat liver transplantation (Shen et al., 2007). We have shown the down-
regulation of annexin 5 in the liver of 3 months old PrPC knockout female mice. This 




outcome suggested that PrPC might be regulating the annexin V levels against the 
cell injury during the pathophysiological conditions.  
5.2.8.2 Annexin A4 and calponin 3 
Similar to annexin 5, annexin A4 and calponin 3 are also calcium binding proteins 
associated with the cytoskeleton, which were down-regulated in the liver of 3 months 
old PrPC knockout mice as compared to the wild type. One study based on gene 
microarray in ME7 and RML mouse strain of prion has shown the up-regulation of 
annexin A4 and calponin 3 (Xiang et al., 2004). It showed a role of PrPC in regulating 
the cytoarchitecture of the cell and loss of its function might be linked with disease 
phenotype.     
5.2.9 Cell proliferation 
5.2.9.1 Putative hydrolase RBBP9   
Putative hydrolase has been reported to be involved in the proliferation of tumor cells 
by suppressing the TGF-β mediated anti-proliferative signaling (Shields et al., 2009). 
We showed a down-regulation of RBBP9 protein in the liver of 14 months old PrPC 
knockout female mice. It showed that PrPC might be involved in the cell proliferation 
signaling during aging liver. As we have also observed fatty liver disease in the 14 
months old PrPC knockout female mice. It could further be relevant in terms of its 
role during the fatty liver disease because the fatty liver disease has also been linked 
to the cell proliferation signaling (Sydor et al., 2013). The increased mitochondrial 
oxidation and the esterification of excessive FFA provide substrates and signaling for 
the cell proliferation. The above evidences suggests that the down-regulation of 
RBBP9 in the liver of 14 months old PrPC knockout female mice might have been 
involved in stimulating the cell proliferation by the activation of TGF- β signaling, 
which might be the part of response mechanism to the reported liver injury due to 
fatty liver disease. The understanding of the detailed regulated signaling linked with 
cell proliferative pathways needs further in detailed investigations.  
5.2.9.2 P27/cyclin dependent kinase inhibitor 1B 
P27/cyclin dependent kinase inhibitor 1B is a cell cycle inhibitor, which negatively 
regulates the progression of G1 cell cycle phase by suppressing the cyclin 
dependent kinase (CDK) activity (Coats et al., 1996; Soos et al., 1996, Toyoshima et 
al., 1994, Chu et al., 2008). The expression of P27 upreglates during Go phase and 




declines when cells enter the cell cycle (Poon et al., 1995; Agrawal et al., 1996; 
Polyak et al., 1994). We have observed the up-regulation of P27/cyclin dependent 
kinase inhibitor 1B in the liver of 9 months old PrPC knockout female as compared to 
the wild type. In support of previous evidences, it has further been suggested that 
PrPC seems to be involved in the cell proliferative pathways. 
5.3 Fatty liver disease 
Liver steatosis is also known as fatty liver disease (FLD) and caused by the abnormal 
deposition of lipids within the liver cells. It is pathologicaly recognized by the large 
vacuoles of triglycerides deposition within the liver cells. Liver steatosis can be 
caused by the intra- as well as extrahepatic mechanisms (Boer et al., 2003). The 
deposition of the higher fat in the liver of PrPC knockout mice showed the 
involvement of PrPC in regulating the lipid metabolism such as the enhanced release 
of non-esterified fatty acids from adipose tissue (lipolysis), increased de novo fatty 
acid synthesis (lipogenesis) or decreased beta-oxidation of fatty acids (Boer et al., 
2003).   
The information regarding the role of PrPC in liver diseases was predicted by IPA 
software analysis of proteomics dataset. The detailed chart (Table – 4) of functional 
network 1 (gastroinestinal disease, hepatic system disease and liver steatosis) 
showed the involvement of various protein clusters in the liver disease pathology. 
Notably, the protein called glutathione-S-transferase zeta 1 (or Maleylacetoacetate 
isomerase) has been predicted to be involved in hepatic steatosis as well as change 
in morphological features of liver tissue as observed in the Sudan III staining. 
Contradictorily, GSTZ1 has been found to be upregulated in 9 months PrPC knockout 
mice liver while the disease pathology has been observed in the 14 months. This 
indicated that the up-regulation of GSTZ1, only in 9 months could be protective 
against steatosis because the deficiency (but not up-regulation) of GSTZ1 has been 
reported to be involved in the liver steatosis (Lim CE et al., 2004). As we have 
observed no regulation of GSTZ1 in the liver of 14 months old mice, which might be 
one of the factor that liver steatosis has been observed only in the liver of 14 months 
old PrPC knockout mice. Other than GSTZ1, several markers of liver steatosis have 
been found in 14 months old female mice liver as well, which are discussed in detail 
in section (5.3.3).    




As a confirmatory finding, the higher levels of triglycerides in the liver of 14 months 
old PrPC knockout mice have been observed by the biochemical test. IPA analysis 
has predicted the 12 protein molecules (Table 4 – Column 6) in the network linked 
with the excessive deposition of triglycerides including glucose-6-phosphotase, 
Peroxisome proliferator-activated receptor alpha (PPARα), Acetyl-CoA 
acetyltransferase1, Insulin receptor and leptin. Out of 12 proteins, PPARα is of 
particular importance (Fig. 23A) because it is a transcriptional factor which regulates 
the various enzymes of lipogenesis as well as beta oxidation of free fatty acids 
(FFAs) (Kersten et al., 2000).  
The understanding of the exact mechanisms which lead to the deposition of 
triglycerides in the liver of PrPC knockout mice needs further investigation.  
















































































5.3.1 Pathology associated with liver steatosis   
Fatty liver disease has been classified into two main categories: alcoholic (ALD) and 
non-alcoholic liver disease (NALD), as no alcohol treatment dose was given, so fatty 
liver disease in this study is NALD. NALD is associated with the multiple pathological 
outcomes ranging from the simple steatosis, nonalcoholic steatohepatitis (NASH), 
fibrosis to liver cirrhosis (Wieckowska et al., 2006).  
Severity of the disease depends on the extent of liver injury such as the involvement 
of cell death due to apoptosis, formation of cytoskeleton protein aggregates called 
Mallory bodies (MD). The formation of MB indicates the progression of the disease 
into the second NASH stage from the simple NALD (Feldstein et al., 2003). Further, 
the increased formation of fibrous scar tissue around the liver cells and the blood 
vessels causes fibrosis and the final advanced stage is called cirrhosis, which is 
marked by the shrinkage of the liver, when tissue becomes lumpsy.  
Sudan III staining has shown the dense fat globules in the liver of 14 months old 
PrPC knockout mice, which is a typical feature of liver steatosis. In addition, the 
density of hepatocytes has been observed less and more spaces in the liver of PrPC 
knockout mice as compared to the wild type. The decrease in the number of 
hepatocytes in the steatotic liver of PrPC knockout mice could be because of 
increased cell death due to apoptosis. To confirm the progression of the disease, we 
further analyzed the expressional regulation of apoptotic markers. Apoptosis can be 
caused by the extrinsic or death receptor pathway and the intrinsic or mitochondrial 
pathway. The induction of apoptosis in the fatty liver disease, activated by the 




production of ROS due to increased oxidation of free fatty acids is already known 
(Wang et al., 2014).  
In liver steatosis, increased de novo fatty acid synthesis or uptake of free fatty acids 
(FFAs) by liver from the adipose tissues triggers the synthesis of triglycerides and 
subsequently, the excessive amounts of fatty acids enter into the mitochondria for 
beta oxidation (Gusdon et al., 2014). The increased rate of free fatty acids (FFAs) 
mitochondrial beta-oxidation during liver steatosis has already been described 
(Lazarin et al., 2011). It leads to the increased transport of the substrates (i.e 
NADH/acetyl CoA) to electron transport chain (ETC) and subsequently, results into 
the higher production of reactive oxygen species (ROS), which may further cause 
ETC dysfunction. Interestingly, we have found the up-regulation of mitochondrial 
enzyme called Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase (DI) in the liver of 14 
months old PrPC knockout mice. DI is involved in the beta oxidation of free fatty 
acids. Additionally, the dysfunction of ETC is indicated by the down-regulation of TCA 
enzymes which were discussed in the section 5.2.2. The current evidences suggest 
that there has been higher production of ROS in the liver of 14 months old PrPC 
knockout mice due to increased fatty acid oxidation.    
The role of ROS in regulating the levels of anti-apoptotic protein bcl2 due to 
increased oxidative stress is very well known (Hildeman et. al., 2003). Bax and Bcl-2 
are anti- and pro-apoptotic members, respectively of the bcl-2 family (Gross et al., 
1999). Additionally, it has been reported that Bax to Bcl-2 ratio increases during the 
fatty liver disease progression due to apoptosis (Walsh et al., 2004). We have shown 
the down-regulation of bcl-2 protein in the liver of 14 months old PrPC knockout mice 
as compared to the wild type by Western blot. There was no significant regulation of 
Bax protein in PrPC knockout mice liver as compared to wild type. Hence, increase in 
Bax to Bcl-2 ratio in the PrPC knockout mice liver confirmed the involvement of 
apoptosis in liver injury associated with the NALD. Thus, it is evident that liver 
steatosis might have been progressed into NASH. Interestingly, the up-regulation of 
bcl2 expression in the brain of PrPC knockout mice has already been described 
(Brown et al., 2002), which evidenced that the down-regulation of bcl2 specifically in 
liver could be a secondary effect due to liver steatosis.   




5.3.2 Change in cytoskeleton function in liver disease 
As discussed previously that the progression of liver steatosis into NASH is marked 
by the apoptosis and formation of cytoskeleton aggregates called Mallory bodies. 
Mallory bodies contain the de-regulated cytoskeleton proteins like keratin and tau. 
The up-regulation of tau protein in the liver steatosis with marked presence of Mallory 
bodies has already been reported (Zatloukal et al., 1995). We have also shown the 
up-regulation of tau in the liver of 14 months old PrPC knockout female mice as 
compared to the wild type by Western blot and immunofluorescence, the evidence 
which supported the progression of NALD. Further, α-smooth muscle actin is known 
as an early marker of hepatic stellate cell activation that plays a role in the induction 
of fibrosis and which could be associated with the progression of liver steatosis 
(Washington et al., 2000, Macdonald et al., 2001, Nouchi et al., 1991). Our 
proteomics dataset has shown 4.96 fold up-regulation of the alpha smooth muscle 
actin in the liver of 14 months old PrPC knockout female mice as compared to the 
wild type. The up-regulation of tau protein and alpha smooth muscle actin in the 
PrPC knockout mice showed that the liver steatosis might have been progressed with 
the advanced cytoskeleton pathology like Mallory body’s formation and liver fibrosis 
(Fig. 23D).   
5.3.3 Markers of liver steatosis (Proteomics dataset)  
5.3.3.1 Sorbitol dehydrogenase (SDH)  
Sorbitol dehydrogenase is an enzyme of carbohydrate metabolism. It catalyzes the 
conversion of sorbitol into fructose. We have observed the up-regulation of SDH in 
the liver of 14 months old PrPC knockout mice as compared to the wild type from our 
proteomics dataset. The higher expression of SDH may increase the synthesis of 
fructose. Interestingly, the reports based on high fed fructose mice have shown the 
induction of liver steatosis by the activation of PPARα (Chan et al., 2012, Zhang et 
al., 2008). Notably, PPARα is an important transcriptional factor (also predicted by 
IPA software analysis – Table 4) which has been known to regulate the expression of 
many enzymes involved in lipid metabolism (Kersten et al., 2000). Additionally, the 
up-regulation of SDH has also been associated with the liver disease pathology 
(Gröhn et. al., 2010). Therefore, it has been evidenced that the up-regulation of SDH 
might be linked with the increased de novo synthesis of fatty acids by the activation 
of PPARα (Fig. 23A and 23E).   




5.3.3.2 Amine sulfotransferase (SULT1A3)   
Amine sulfotransferases have been known to catalyze the sulfonation of xenobiotics 
such as dopamine, norepinephrine, catechols, monocyclic phenols and aromatic 
molecules and also regulate the hormonal levels (Jancova et al., 2010). 
 
Fig. 23. Liver steatosis: possible biochemical defects and pathological outcome in the liver 
of 14 months old PrPC knockout mice. (A) PPARα, a transcriptional factor regulating the 
enzymes involved in the lipid metabolism (predicted by IPA analysis), (B) ER stress, caused 
by the down-regulation of chaperone activity (GRP75), (C) The induction of apoptosis by 
Bax/Bcl2, (D) The cytoskeleton disturbance during progression of steatosis caused by the 
regulation of tau and alpha smooth muscle actin, (E) The role of sorbitol dehydrogenase and 
malate dehydrogenase in liver steatosis.  
  
The sulfonation of xenobiotics increases their polarity and solubility which is required 
for their transport out of the cell. Although the exact role of sult1a3 in liver steatosis is 
not known, but recently, the reduced levels of various forms of sulfotransferase 
including (SULT1A3) in the liver of patients with steatosis and cirrhosis has been 
reported (Yalcin et al., 2013). Interestingly, we have found 3.01 fold down-regulation 
of sult1a3 in the liver of 14 months old PrPC knockout female mice. The down-
regulation of sulfotransferase may alter its function to detoxify its various substrates 




and could result into the increased hepatotoxicity associated with the liver steatosis in 
the liver of 14 months old PrPC knockout mice.  
5.3.3.3 Apolipoprotein A-1(Marker) 
ApoA-I has already been discussed in the context of PrPC function (section – 5.2.5). 
It is a component of high density lipoprotein (HDL) in the plasma. ApoA-I has been 
involved in the efflux of fat such as cholesterol from the peripheral tissues to the liver, 
which is then excreted out of the body. Although, the role of Apolipoprotein A-1 in the 
development of liver disease is not clear but the co-localization of Apo-A1 with fat 
globules in the liver steatosis has been described in an H-ras12V transgenic model 
(Wang et al., 2011). We have found the up-regulation of Apo-A1 in the liver of 14 
months old PrPC knockout mice as compared to the wild type. Hence, the up-
regulation Apo-A1 in the liver of PrPC knockout mice indicated that it might be 
involved in the development of fatty liver disease pathology.   
5.3.3.4 Malate dehydrogenase (Marker) 
As already discussed in the bioenergetics section (section 5.2.2.2), it is an enzyme of 
citric acid metabolism and has been found to be down regulated in the liver of 14 
months old PrPC knockout female mice. The down-regulation of MDH could lead to 
the slowing down of biochemical reactions in the TCA cycle and subsequently, may 
cause the accumulation of citrate and acetyl CoA. Acetyl CoA is also a substrate of 
de novo fatty acid synthesis. The up-regulation of lipogenesis due to allosteric 
activation of acetyl CoA carboxylase (Munday et al., 2002, first rate limiting enzyme 
of lipogenesis) by citrate might be part of the mechanism of the observed fatty liver 
disease in the liver of 14 months old PrPC knockout group (Fig. 23E).                                               
5.3.3.5 Proteins with chaperone activity 
All three proteins are the enzymes known to have chaperone activity along with the 
role against oxidative stress. This cluster of proteins have been observed to be 1.56 
fold down regulated in the liver of 14 months old PrPC knockout female mice as 
compared to the wild type.   
5.3.3.5.1 Protein disulfide-isomerase 
It is involved in protein folding by re-arranging the disulfide bonds (B. Wilkinson et al., 
2004). A proteomics based study from chang’s group has shown the down-regulation 
of protein disulfide-isomerase A4 in the liver of obese CP rat (hypertensive/NIH –




corpulent rat SHR/NDmcr-cp) as compared to the control groups (Chang et al., 
2012). Hence, the down-regulation of protein disulfide-isomerase A4 in the liver of 14 
months old PrPC knockout mice correlated with the previous finding that it might be 
linked with the lipid metabolism. Therefore, the down-regulation of protein disulfide-
isomerase A4 could generate the higher endoplasmic reticulum (ER) stress and 
subsequent increased unfolded protein responses (UPR) which may further induce 
apoptosis (Davenport et al., 2007, Arsenovic et al., 2012). The alteration of the lipid 
metabolism due to ER stress has already been described in several liver diseases 
including the fatty liver disease (Malhi et al., 2011). The Knockout of PrPC appears to 
be linked with endoplasmic reticulum (ER) stress induced liver steatosis hypothesis, 
which needs further investigation.  
5.3.3.5.2 Stress-70 (GRP75)  
It has been known to be involved in the multiple functions such as chaperone activity, 
mitochondrial transporter, and regulation of the lipid pathways and exist in multiple 
locations within the cell (Wadhwa et al., 2002, Mizzen et al., 1991). We have found 
the down-regulation of GRP75 in the proteomics dataset and also validated its 
regulation at the gene level by qPCR (Index – Fig. 2). GRP75 has been 
demonstrated to be an interacting partner of GRP94 (Takano et al 2001) and GRP94 
is further known to be regulated by PPARα (Macdonald et al., 2000). As discussed 
previously, PPARα is a transcriptional factor which regulates various enzymes of lipid 
metabolism (Fig. 23A). The above evidences indicated that the down-regulation of 
GRP75 might be linked with the change of genes expressions which regulate the lipid 
metabolism.  
In liver, both in in vivo and in vitro studies based on CCl4 induced liver injury have 
shown that the over-expression of GRP75 expression protects against oxidative 
damage by the inhibition of cytochrome C release, improve cell viability, ATP 
concentrations and decreasing the serum levels of alanine transaminase and 
aspartate aminotransferase (Qiukai et al., 2013). As progression of liver steatosis 
leads to liver injury, increase in oxidative stress and tissue fibrosis. The down-
regulation of GRP75 suggests its involvement in liver disease pathology in the liver of 
14 months old PrPC knockout mice.  
Additionally, GRP75 has also been demonstrated to be an interacting partner of p53 
and described to inactivate the p53 activity (Wadhwa et al., 2002). P53 is a very well-




known protein which generates the death signals to mitochondria and cause 
apoptosis (Marchenko et al 2000). Hence, the activation of p53 could be favored by 
the down-regulation of GRP75 and subsequently may cause the induction of hepatic 
apoptosis in the liver of 14 months old PrPC knockout mice.   
The above evidences showed that the function of GRP75 as an anti-oxidant, as an 
anti-apoptotic factor and its probable role in the lipid metabolism could be modulated 
by the PrPC expression in the old age liver. The down-regulation of GRP75 in the 
liver of 14 months old PrPC knockout female mice seems, at least partially be 
responsible of the observed pathological phenotype in the PrPC knockout mice liver.  
5.3.3.5.3 Heat shock cognate 71 kDa protein (HSC 71) 
It is an important protein which has chaperone properties and regulates the protein 
maturation (Beckmann et al., 1990; Beckmann et al., 1992). It also plays a role in the 
translocation of the proteins into endoplasmic reticulum (ER) and mitochondria 
(Chirico et al., 1998, Sheffield et al., 1990). Hsc70 has already been described as an 
interactive partner of recombinant PrP as well as native PrP (Wilkins et al., 2010). 
Similar to the disulfide isomerase A4 and stress-70 proteins, the down-regulation of 
hsc70 might be a causative factor for endoplasmic reticulum (ER) stress, apparently 
because of its reduced chaperone activity. As mentioned previously, the endoplasmic 
reticulum (ER) stress has been known to be linked to ROS mediated liver injury and 
thereby, further involved in the progression of the liver steatosis into NASH.  
5.4 Age and PrPC dependent altered tau/ptau pathway 
As we have discussed previously, that the regulation of tau protein has been known 
to be linked with the cytoskeleton disturbance during liver steatosis. It was one of our 
interests to describe the tau protein function in detail because of very well established 
role of PrPC in regulating tau function in prion diseases (Benvegnù et al., 2011, 
Reiniger et al., 2011). In addition, IPA software analysis of liver proteomics dataset 
also predicted the involvement of tau function (additional analysis with brain as a 
reference tissue). Tau is a microtubule associated protein, which stabilizes the 
microtubule. The hyperphosphorylation of tau causes its dissociation from the 
microtubules which eventually lead to its destablization and imbalance of the 
cytoskeleton (Illenberger et al., 1998). The role of PrPC in regulating the tau function 
has already been described in the brain hippocampus using PrPC knockout mouse 
model and also during neurodegnerative diseases (Benvegnù et al., 2011, Reiniger 




et al., 2011). A report showed that the treatment of neurotoxic prion synthetic peptide 
(106-126) to cultured neurons induced the cell death and in parallel caused the up- 
regulation of tau phosphorylation by the activation of gsk3beta activity (Perez et al., 
2003).     
First, we showed the age dependent decrease of total tau protein expression in the 
liver of PrPC knockout mice as well as in the wild type mice. Secondly, we showed 
the significant up-regulation of ptau expression in the liver of 14 months old 
compared to 3 and 9 months old wild type mice. However, the increased 
phosphorylation of tau could be a mechanism linked with the higher degradation of 
tau protein in the old age (Shimura et al., 2004), which has been indicated by no 
parallel significant decrease in mRNA expression of tau gene (Data not shown) as 
compared to the protein expression of total tau with aging. Interestingly, we observed 
the down-regulation of ptau expression in the liver of 14 months old PrPC knockout 
mice as compared to the wild type mice. Therefore, the higher tau protein 
degradation due to phosphorylation of tau protein in the aging mice could be a PrPC 
dependent mechanism to regulate the cytoskeleton functions in the liver tissue.                        
Further, gsk3beta and Cdk5 are among the well characterized enzymes which 
catalyzes the phosphorylation of tau in various neurodegenerative pathways 
(Ishiguro K, et al., 1993, Takashima A, et al., 2006). The activation of gsk3beta 
depends on its phosphorylation at Tyr216 residue while the activation of Cdk5 
depends on its interaction with the p25 fragment. Hence, we analyzed the 
expressional regulation of gsk3beta/pgsk3beta and Cdk5/p25 proteins. We showed 
the down-regulation of pgsk3beta/gsk3beta enzyme (phospho-Tyr216) expression in 
the liver of 14 months old PrPC knockout mice while there was no such regulation in 
p25/Cdk5 expressions. As described before, the expression of ptau was also down-
regulated in the liver of 14 months old PrPC knockout mice liver. Therefore, it 
indicated that PrPC might be involved in the tau protein phosphorylation in the liver of 
14 months old mice by regulating the gsk3beta enzyme activation. Alterations in the 
phosphorylation of tau modulates its cytoskeleton function, because binding of tau 
protein to the microtubule, stabilizes the microtubule assemblies. The increased 
phosphorylation of tau protein decreases its binding to the microtubules while 
decrease in phosphorylation causes increased binding. 




Current evidences showed a role of PrPC in the regulation of age related alterations 






 PrPC seems to play an important role in the liver of aging mice which is   
indicated by the significant up-regulation of PrPC expression in the liver of 
aging wild type mice as compared to the adult or advanced adult age mice.   
 The evidences of the observed fatty liver disease pathology in the liver of 
aging PrPC knockout mice were provided by the implication of 2D gel 
proteome profiling.  
 Current study revealed a new role of PrPC in regulating the pathways linked 
with the lipid/glucose metabolism in the liver. The manifestation of apoptosis in 
the damaged tissue as indicated by the higher Bax/Bcl2 ratio along with the 
markers of liver steatosis found in the proteomics dataset, revealed a possible 
progression of the disease into non-alcoholic steatohepatitis (NASH).  
 The regulation of G6PC, GPD1, GSTZ1, INSR, LDLR, LEP, LPL, NR1H3, 
NR1H4, POR, PPARα, PPARGCA, and SIRT3 (predicted by the bio-
informatics IPA software analysis) proteins shows an imbalance of the 
complex metabolic pathways in the liver of aging PrPC knockout mice.  
 The above outcome revealed that the regulations of the lipid or glucose 
metabolism in the intra- or extra-hepatic tissues are among the causative 
factors of the observed liver disease phenotypes, which needs further in 
detailed investigations.  
 Interestingly, the expression of PrPC was higher in the liver of aging wild type 
female mice than male and the observed liver disease also affects more to the 
female group after knock out of PrPC gene. It indicates that, possibly due to 
the hormonal influence, gender seems to play a differential role in regulating 
the PrPC function in the liver.  
 Additionally, the down-regulation of ptau expression in the liver of aging PrPC 
knockout mice via gsk3beta showed a role of PrPC in regulating the 
cytoskeleton function in the aging mice liver.  
 In the current study, with the help of proteomics approach, a new role of PrPC 
in regulating the glucose/lipid metabolic pathways has been described, which 
also further seems be linked with the cytoskeleton functions in the aging liver. 





Take home message 
The finding of fatty liver disease along with the alteration of cytoskeleton protein tau 
function in the liver of aging PrPC knockout mice revealed an important metabolic 
role of PrPC in the aging mice liver. 
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        Table 1 – Network 1 liver 





ATP7B ATPase, Cu++ transporting, beta polypeptide   Cytoplasm 
ECH1 enoyl CoA hydratase 1, peroxisomal O35459 6.71 Cytoplasm 
FDPS farnesyl diphosphate synthase Q920E5 -2.28 Cytoplasm 
FTH1 ferritin, heavy polypeptide 1 P09528 2.08 Cytoplasm 
G6PC glucose-6-phosphatase, catalytic subunit   Cytoplasm 
GPD1 glycerol-3-phosphate dehydrogenase 1 
(soluble) 
  Cytoplasm 
GSTT2/GSTT2
B 
glutathione S-transferase theta 2   Cytoplasm 
GSTZ1 glutathione S-transferase zeta 1 Q9WVL0 2.3 Cytoplasm 
HIST1H1C histone cluster 1, H1c P15864 -2.48 Nucleus 
IDH3A isocitrate dehydrogenase 3 (NAD+) alpha Q9D6R2 -2.29 Cytoplasm 
INSR insulin receptor   Plasma 
Membrane 
LEP Leptin   Extracellul
ar Space 
MAPK14 mitogen-activated protein kinase 14   Cytoplasm 
MDH2 malate dehydrogenase 2, NAD (mitochondrial)   Cytoplasm 
MRPL12 mitochondrial ribosomal protein L12 Q9DB15 2.07 Cytoplasm 
NDUFV2 NADH dehydrogenase (ubiquinone) 
flavoprotein 2, 24kDa 
Q9D6J6 -1.8 Cytoplasm 
NFE2L2 nuclear factor, erythroid 2-like 2   Nucleus 
NR1H4 nuclear receptor subfamily 1, group H, 
member 4 
  Nucleus 
POR P450 (cytochrome) oxidoreductase   Cytoplasm 
PPA1 pyrophosphatase (inorganic) 1   Cytoplasm 
PPARA peroxisome proliferator-activated receptor 
alpha 
  Nucleus 
PPARGC1A peroxisome proliferator-activated receptor 
gamma, coactivator 1 alpha 
  Nucleus 
PSMA7 proteasome (prosome, macropain) subunit, 
alpha type, 7 
  Cytoplasm 
PSMB4 proteasome (prosome, macropain) subunit, 
beta type, 4 
  Cytoplasm 
PSMC3 proteasome (prosome, macropain) 26S 
subunit, ATPase, 3 
  Nucleus 




PSMD14 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 14 
  Cytoplasm 
PSMD7 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 7 
  Cytoplasm 
RICTOR RPTOR independent companion of MTOR, 
complex 2 
  Cytoplasm 
RPLP0 ribosomal protein, large, P0   Cytoplasm 
Rps3a1 ribosomal protein S3A1 P97351 -2.15 Cytoplasm 
SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), 
member 1 
Q9D154 2.23 Cytoplasm 
SIRT3 sirtuin 3   Cytoplasm 
TALDO1 transaldolase 1 Q93092 -1.82 Cytoplasm 
THRB thyroid hormone receptor, beta   Nucleus 
TPI1 triosephosphate isomerase 1 P17751 2.29 Cytoplasm 
          
          Table 2 – Network 2 liver 





ATP7B ATPase, Cu++ transporting, beta 
polypeptide 
  Cytoplasm 
ECH1 enoyl CoA hydratase 1, peroxisomal O35459 6.71 Cytoplasm 
FDPS farnesyl diphosphate synthase Q920E5 -2.28 Cytoplasm 
FTH1 ferritin, heavy polypeptide 1 P09528 2.08 Cytoplasm 
G6PC glucose-6-phosphatase, catalytic subunit   Cytoplasm 
GPD1 glycerol-3-phosphate dehydrogenase 1 
(soluble) 
  Cytoplasm 
GSTT2/GSTT2B glutathione S-transferase theta 2   Cytoplasm 
GSTZ1 glutathione S-transferase zeta 1 Q9WVL0 2.3 Cytoplasm 
HIST1H1C histone cluster 1, H1c P15864 -2.48 Nucleus 
IDH3A isocitrate dehydrogenase 3 (NAD+) 
alpha 
Q9D6R2 -2.29 Cytoplasm 
INSR insulin receptor   Plasma 
Membrane 
LEP Leptin   Extracellul
ar Space 
MAPK14 mitogen-activated protein kinase 14   Cytoplasm 
MDH2 malate dehydrogenase 2, NAD 
(mitochondrial) 
  Cytoplasm 
MRPL12 mitochondrial ribosomal protein L12 Q9DB15 2.07 Cytoplasm 









NADH dehydrogenase (ubiquinone) 










NFE2L2 nuclear factor, erythroid 2-like 2   Nucleus 
NR1H4 nuclear receptor subfamily 1, group H, 
member 4 
  Nucleus 
POR P450 (cytochrome) oxidoreductase   Cytoplasm 
PPA1 pyrophosphatase (inorganic) 1   Cytoplasm 
PPARA peroxisome proliferator-activated 
receptor alpha 
  Nucleus 
PPARGC1A peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha 
  Nucleus 
PSMA7 proteasome (prosome, macropain) 
subunit, alpha type, 7 
  Cytoplasm 
PSMB4 proteasome (prosome, macropain) 
subunit, beta type, 4 
  Cytoplasm 
PSMC3 proteasome (prosome, macropain) 26S 
subunit, ATPase, 3 
  Nucleus 
PSMD14 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 14 
  Cytoplasm 
PSMD7 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 7 
  Cytoplasm 
RICTOR RPTOR independent companion of 
MTOR, complex 2 
  Cytoplasm 
RPLP0 ribosomal protein, large, P0   Cytoplasm 
Rps3a1 ribosomal protein S3A1 P97351 -2.15 Cytoplasm 
SERPINB1 serpin peptidase inhibitor, clade B 
(ovalbumin), member 1 
Q9D154 2.23 Cytoplasm 
SIRT3 sirtuin 3   Cytoplasm 
TALDO1 transaldolase 1 Q93092 -1.82 Cytoplasm 
THRB thyroid hormone receptor, beta   Nucleus 
TPI1 triosephosphate isomerase 1 P17751 2.29 Cytoplasm 
 
          Table 3 – Network 3 liver 





ACTA2 actin, alpha 2, smooth muscle, aorta P62737 -4.96 Cytoplasm 
ACY1 aminoacylase 1 Q99JW2 -2.06 Cytoplasm 
AHR aryl hydrocarbon receptor   Nucleus 
APOA4 apolipoprotein A-IV   Extracellul
ar Space 




C6 complement component 6   Extracellul
ar Space 
CCND1 cyclin D1   Nucleus 
CDKN1B cyclin-dependent kinase inhibitor 1B 
(p27, Kip1) 
P46414 2.32 Nucleus 
CTNNB1 catenin (cadherin-associated protein), 
beta 1, 88kDa 
  Nucleus 
CYP1A2 cytochrome P450, family 1, subfamily A, 
polypeptide 2 
  Cytoplasm 
Cyp2d9 (includes 
others) 
cytochrome P450, family 2, subfamily d, 
polypeptide 9 
  Cytoplasm 
CYP2E1 cytochrome P450, family 2, subfamily E, 
polypeptide 1 
  Cytoplasm 
EFTUD2 elongation factor Tu GTP binding 
domain containing 2 
O08810 -1.81 Nucleus 
Gm4794/Sult3a1 sulfotransferase family 3A, member 1 O35403 -3.01 Cytoplasm 




Igtp interferon gamma induced GTPase   Cytoplasm 
Mt1 metallothionein 1   Cytoplasm 
PPARD peroxisome proliferator-activated 
receptor delta 
  Nucleus 
RGN Regucalcin Q64374 -1.59 Nucleus 
SCD stearoyl-CoA desaturase (delta-9-
desaturase) 
  Cytoplasm 
SLC13A1 solute carrier family 13 (sodium/sulfate 
symporter), member 1 
  Plasma 
Membrane 
Slco1a1 solute carrier organic anion transporter 
family, member 1a1 
  Plasma 
Membrane 
SMAD7 SMAD family member 7   Nucleus 
SORD sorbitol dehydrogenase Q64442 2.24 Cytoplasm 
STAT1 signal transducer and activator of 
transcription 1, 91kDa 
  Nucleus 
VLDLR very low density lipoprotein receptor   Plasma 
Membrane 
XBP1 X-box binding protein 1   Nucleus 
 
 
ACTB actin, beta P60710 -2,480 Cytoplasm 
MAFB v-maf avian musculoaponeurotic 
fibrosarcoma oncogene homolog B 
--   Nucleus 




       Table 4 – Brain networks 
ID Molecules in Network Score Focus 
Molecules 
Top Diseases and 
Functions 
1 ACTB,NAPA,RARA,YWHAG 7 3 Cellular Development, 
Nervous System Development 
and Function, Tissue 
Development 
2 ADCYAP1,SERPINB1 2 1 Cancer, Cell Morphology, Cell-
To-Cell Signaling and 
Interaction 
3 KMT2D,SORD 2 1 Carbohydrate Metabolism, 
Small Molecule Biochemistry, 
Developmental Disorder 
4 CTSZ,PSEN1,PSEN2 2 1 Hereditary Disorder, Metabolic 
Disease, Nervous System 
Development and Function 
5 FDPS,NR1H2,NR1H3 2 1 Endocrine System 
Development and Function, 
Endocrine System Disorders, 
Nervous System Development 
and Function 






1 1 Cellular Development, Cellular 









       Table 5 – Calculations for PrPC expression (Capillary electrophoreis) 
    Female          Male         
























  1  152177  281386  122857  2,29 348539,17 152668 281386 122857  2,29  349663
,74 
  2  127967  281386  122857  2,29 293089,71 122926 281386 122857  2,29  281544
,03 
  3  140734  281386  122857  2,29 322330,66 145240 281386 122857  2,29  332650
,99 
  4  140970  281386  122857  2,29 322871,18 124735 281386 122857  2,29  285687
,28 

















  1  130441  253032  77815,77  3,25 424152,44 108443 253032 77815,8  3,25  352621
,98 
  2  118011  253032  77815,77  3,25 383734,05 105078 253032 77815,8  3,25  341680
,07 
  3  103925  253032  77815,77  3,25 337930,88 104728 253032 77815,8  3,25  340541
,98 




  4  118494  253032  77815,77  3,25 385304,61 109282 253032 77815,8  3,25  355350
,14 
  5  118813  253032  77815,77  3,25 386341,9 89887,8 253032 77815,8  3,25  292286
,4 
  6  108398  253032  77815,77  3,25 352475,65 84926,5 253032 77815,8  3,25  276153
,83 
  7  115977  253032  77815,77  3,25 377120,13 77627,4 253032 77815,8  3,25  252419
,5 
  8  134676  253032  77815,77  3,25 437923,3 84872,9 253032 77815,8  3,25  275979
,54 
  9  116750  253032  77815,77  3,25 379633,68          
  10  105437  253032  77815,77  3,25 342847,42          
  11  91018,8  253032  77815,77  3,25 295964,05          
14 M    Femal
e 















  1  174798  398009  106104  3,75 655688,54 137857 398009 106104  3,75  517118
,36 
  2  149768  398009  106104  3,75 561797,97 118734 398009 106104  3,75  445385
,67 
  3  174050  398009  106104  3,75 652882,7 138651 398009 106104  3,75  520096
,75 
  4  196334  398009  106104  3,75 736472,7 141586 398009 106104  3,75  531106
,29 
 





Fig.1. Functional classification based on PrPC dependent regulated proteins: (A) Total 
set of proteins regulated in PrP knockout mice liver as compared to wild type mice from all 
the groups. Major categories included Protein/Amino acid metabolism, lipid metabolism, and 
energy metabolism, gene/mRNA splicing. (B) and (C), sub-classification of regulated proteins 
from male and female groups respectively, shows a sex-dependent regulation of proteins 
from different categories with mRNA splicing group only present in male. 
 
 





Fig. 2. Stress-70/GRP75 mRNA expression in 14 months old female mice liver: 
Significant higher expression of stress-70 mRNA in 14 months old female PrPC knockout 





















Methanol  Milipore(MERCK) 
Acetic acid   Milipore(MERCK) 
Sodium thiosulphate  Sigma 
Silver nitate  milipore(MERCK) 
Formaldehyde  Sigma 
Sodium carbonate  ROTH 
Acetone  Milipore(MERCK) 
Triton X-100  ROTH 
PBS  Milipore(MERCK) 
BSA  ROTH 
Luminol  Sigma 
Dimehyl sulphate (DMSO)  Sigma 
p-Coumarsöure  ROTH 
Tris (Base)  ROTH 
Tris (HCl)  ROTH 
HCl   Fluka 
 
ECL Solution 
Solution 1 (10ml) 
100 µl of 250mM Luminol (0.44g/10 ml DMSO) 
44 µl of 90mM p-Coumarsäure (15g/10ml DMSO) 
1ml of 1.M Tris/HCL pH -8.5 
8.85 ml H2O 
Solution 2 (10ml) 
6 µl of 30% H2O2 
1 ml of Tris/HCL pH – 8.5 





Mouse age terminology Years 
Aging mice 14 months 
Advanced adult age mice 9 months 
Adult age mice 3 months 
Gasperini et al., 2014 
    
Sr. No. Abbreviation Complete name 
1 AD Alzheimer's disease 
2 Aβ Amlyoid beta 
3 BAX Bcl2-associated X protein 
4 Bcl2 B-cell lymphoma 2 
5 BSA Bovine serum albumin 
6 BSE Bovine spongiform encephalopathy  
7 CCl4 Carbon tetrachloride 
8 CDK Cyclin dependent kinase  
9 CDK5 Cyclin dependent kinase 5  
10 CE Capillary electrophoresis  
11 CFA Cafeteria 
12 CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate 
13 CJD Creutzfeldt-Jakob disease  
15 DI Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase 
16 Dpl Dopple 
17 DTT Dithiothreitol 
18 ELISA Enzyme-linked immunosorbent assay  
19 ESI-Q-TOF Electrospray ionization quadrupole time-of-flight 
mass spectrometry 
20 ETC Electron transport chain  
21 FDC Follicular dendritic cells  
22 FFAs Free Fatty acids 




23 FFI Fatal familial insomnia  
24 FITC Fluorescein isothiocyanate  
25 FLD Fatty liver disease  
26 FPP synthase Farnesyl pyrophosphate synthase  
27 GPI Glycosyl-phosphatidylinositol  
28 Gsk3Beta Glycogen synthase kinase 3 beta 
29 GSTZ1 Glutathione-S-transferase zeta 1  
30 HAAO-3 3-hydroxyanthranilate 3, 4-dioxygenase  
31 HSC 71 Heat shock cognate 71 kDa  
32 HSCs Hepatic stellate cells 
33 INSR Insulin receptor 
34 IPA Ingenuity pathway analysis 
35 IPKB Ingenuity Pathways Knowledge Base  
36 MAPT Microtubule associated protein tau  
37 MD Mallory bodies  
38 MDH Malate dehydrogenase  
39 NALD Non-alcoholic liver disease  
40 NASH Non-alcoholic steatohepatitis  
41 ORF Open reading frame  
42 p53 Phosphoprotein 53 
43 PAGE Poly acrylamide gel electrophoresis 
44 P-gsk3Beta Phospho - Glycogen synthase kinase 3 beta 
45 PPARα Peroxisome proliferator-activated receptor alpha  
46 PrPC Cellular prion protein 
47 PrPSc Scrapie prion protein 
48 PVDF Polyvinylidene fluoride 
49 RFU Relative Fluorescent Units 
50 ROS Reactive oxygen species  
51 SDH Sorbitol dehydrogenase  
52 SDS Sodium dodecyl sulfate 
53 SOD Superoxide dismutase  
54 STRAP Serine-threonine kinase receptor-associated protein  






Glucose-regulated protein 75 
56 SULT1A3 Sulfotransferase including  
57 TAP 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-
yl]amino]propane-1-sulfonic acid 
58 TGF- β Transforming growth factor beta 
59 TSEs Transmissible spongiform encephalopathies 
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